WO2001096584A2 - Materials and methods for the control of nematodes - Google Patents
Materials and methods for the control of nematodes Download PDFInfo
- Publication number
- WO2001096584A2 WO2001096584A2 PCT/US2001/018911 US0118911W WO0196584A2 WO 2001096584 A2 WO2001096584 A2 WO 2001096584A2 US 0118911 W US0118911 W US 0118911W WO 0196584 A2 WO0196584 A2 WO 0196584A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- dna sequence
- molecule according
- rnai molecule
- rnai
- Prior art date
Links
- 241000244206 Nematoda Species 0.000 title claims abstract description 118
- 238000000034 method Methods 0.000 title claims abstract description 50
- 239000000463 material Substances 0.000 title description 8
- 230000009368 gene silencing by RNA Effects 0.000 claims abstract description 275
- 108091030071 RNAI Proteins 0.000 claims abstract description 157
- 239000000203 mixture Substances 0.000 claims abstract description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 151
- 108090000623 proteins and genes Proteins 0.000 claims description 151
- 241000196324 Embryophyta Species 0.000 claims description 68
- 108020004414 DNA Proteins 0.000 claims description 31
- 239000002773 nucleotide Substances 0.000 claims description 25
- 125000003729 nucleotide group Chemical group 0.000 claims description 25
- 230000009261 transgenic effect Effects 0.000 claims description 19
- 239000013598 vector Substances 0.000 claims description 15
- 241000219194 Arabidopsis Species 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 6
- 235000016623 Fragaria vesca Nutrition 0.000 claims description 3
- 235000011363 Fragaria x ananassa Nutrition 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims description 3
- 210000003462 vein Anatomy 0.000 claims description 3
- 102000003992 Peroxidases Human genes 0.000 claims description 2
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims description 2
- 235000011613 Pinus brutia Nutrition 0.000 claims description 2
- 241000018646 Pinus brutia Species 0.000 claims description 2
- 230000033077 cellular process Effects 0.000 claims description 2
- 241000220223 Fragaria Species 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108030003594 Diaminopimelate decarboxylases Proteins 0.000 claims 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 claims 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 claims 1
- 101710162629 Trypsin inhibitor Proteins 0.000 claims 1
- 229940122618 Trypsin inhibitor Drugs 0.000 claims 1
- 102000044159 Ubiquitin Human genes 0.000 claims 1
- 108090000848 Ubiquitin Proteins 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000002438 mitochondrial effect Effects 0.000 claims 1
- 102000004251 pectinacetylesterase Human genes 0.000 claims 1
- 108010072638 pectinacetylesterase Proteins 0.000 claims 1
- 108040007629 peroxidase activity proteins Proteins 0.000 claims 1
- 108091005703 transmembrane proteins Proteins 0.000 claims 1
- 239000002753 trypsin inhibitor Substances 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 abstract description 67
- 108091033319 polynucleotide Proteins 0.000 abstract description 67
- 239000002157 polynucleotide Substances 0.000 abstract description 67
- 102000004169 proteins and genes Human genes 0.000 description 50
- 239000000523 sample Substances 0.000 description 38
- 210000004027 cell Anatomy 0.000 description 36
- 239000012634 fragment Substances 0.000 description 22
- 230000014509 gene expression Effects 0.000 description 22
- 238000009396 hybridization Methods 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 17
- 241000243785 Meloidogyne javanica Species 0.000 description 15
- 235000013601 eggs Nutrition 0.000 description 15
- 238000004519 manufacturing process Methods 0.000 description 14
- 230000009466 transformation Effects 0.000 description 14
- 241000589156 Agrobacterium rhizogenes Species 0.000 description 13
- 241000589158 Agrobacterium Species 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 230000000692 anti-sense effect Effects 0.000 description 12
- 239000013615 primer Substances 0.000 description 12
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 11
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 11
- 230000004071 biological effect Effects 0.000 description 11
- 230000002068 genetic effect Effects 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- 230000003071 parasitic effect Effects 0.000 description 11
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 10
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 230000037431 insertion Effects 0.000 description 10
- 238000003780 insertion Methods 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 9
- 230000035772 mutation Effects 0.000 description 9
- 241000607479 Yersinia pestis Species 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 244000005700 microbiome Species 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 239000013605 shuttle vector Substances 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- 230000000295 complement effect Effects 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- 238000012217 deletion Methods 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 239000003623 enhancer Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000010561 standard procedure Methods 0.000 description 7
- 125000003275 alpha amino acid group Chemical group 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 230000001276 controlling effect Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 230000024241 parasitism Effects 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 241000219310 Beta vulgaris subsp. vulgaris Species 0.000 description 5
- 244000068988 Glycine max Species 0.000 description 5
- 235000010469 Glycine max Nutrition 0.000 description 5
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 5
- 241000193953 Pratylenchus scribneri Species 0.000 description 5
- 240000003768 Solanum lycopersicum Species 0.000 description 5
- 235000021536 Sugar beet Nutrition 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 210000004907 gland Anatomy 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000000520 microinjection Methods 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 239000002689 soil Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 241000219195 Arabidopsis thaliana Species 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000004520 electroporation Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000007613 environmental effect Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 229930027917 kanamycin Natural products 0.000 description 4
- 229960000318 kanamycin Drugs 0.000 description 4
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 4
- 229930182823 kanamycin A Natural products 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 230000002285 radioactive effect Effects 0.000 description 4
- 238000002791 soaking Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 230000014616 translation Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 230000035899 viability Effects 0.000 description 4
- 239000005660 Abamectin Substances 0.000 description 3
- 241000244203 Caenorhabditis elegans Species 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 238000004166 bioassay Methods 0.000 description 3
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 3
- 229960003669 carbenicillin Drugs 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 230000030279 gene silencing Effects 0.000 description 3
- 238000012226 gene silencing method Methods 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000002751 oligonucleotide probe Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 230000001018 virulence Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- ZBMRKNMTMPPMMK-UHFFFAOYSA-N 2-amino-4-[hydroxy(methyl)phosphoryl]butanoic acid;azane Chemical compound [NH4+].CP(O)(=O)CCC(N)C([O-])=O ZBMRKNMTMPPMMK-UHFFFAOYSA-N 0.000 description 2
- CWGATOJEFAKFBK-PDVFGPFMSA-N 5-o-demethyl-22,23-dihydro-23-hydroxy-(13r,23s)-avermectin a1a Chemical compound C1[C@H](O)[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 CWGATOJEFAKFBK-PDVFGPFMSA-N 0.000 description 2
- -1 Acaracides Substances 0.000 description 2
- 241000589155 Agrobacterium tumefaciens Species 0.000 description 2
- 240000001592 Amaranthus caudatus Species 0.000 description 2
- 235000009328 Amaranthus caudatus Nutrition 0.000 description 2
- DJHGAFSJWGLOIV-UHFFFAOYSA-K Arsenate3- Chemical compound [O-][As]([O-])([O-])=O DJHGAFSJWGLOIV-UHFFFAOYSA-K 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 241000482313 Globodera ellingtonae Species 0.000 description 2
- 241001442497 Globodera rostochiensis Species 0.000 description 2
- 241000379510 Heterodera schachtii Species 0.000 description 2
- 241001143352 Meloidogyne Species 0.000 description 2
- 241000243786 Meloidogyne incognita Species 0.000 description 2
- 208000000291 Nematode infections Diseases 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 108700005078 Synthetic Genes Proteins 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- OJOBTAOGJIWAGB-UHFFFAOYSA-N acetosyringone Chemical compound COC1=CC(C(C)=O)=CC(OC)=C1O OJOBTAOGJIWAGB-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 235000012735 amaranth Nutrition 0.000 description 2
- 239000004178 amaranth Substances 0.000 description 2
- 230000001679 anti-nematodal effect Effects 0.000 description 2
- 229940000489 arsenate Drugs 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000007844 bleaching agent Substances 0.000 description 2
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 108091036078 conserved sequence Proteins 0.000 description 2
- 238000011217 control strategy Methods 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 244000079386 endoparasite Species 0.000 description 2
- 230000008124 floral development Effects 0.000 description 2
- 238000003958 fumigation Methods 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000000869 mutational effect Effects 0.000 description 2
- 239000005645 nematicide Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000002987 primer (paints) Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000033458 reproduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000004739 secretory vesicle Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 241000589220 Acetobacter Species 0.000 description 1
- 241000383887 Acrobeloides maximus Species 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241000588986 Alcaligenes Species 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 241000186063 Arthrobacter Species 0.000 description 1
- 241000223651 Aureobasidium Species 0.000 description 1
- 241000589151 Azotobacter Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 108700003918 Bacillus Thuringiensis insecticidal crystal Proteins 0.000 description 1
- 241000193388 Bacillus thuringiensis Species 0.000 description 1
- 108091032955 Bacterial small RNA Proteins 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000009849 Cucumis sativus Nutrition 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 239000005644 Dazomet Substances 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000588698 Erwinia Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 244000307700 Fragaria vesca Species 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 241001442498 Globodera Species 0.000 description 1
- 241001480224 Heterodera Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 206010061217 Infestation Diseases 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 241000235649 Kluyveromyces Species 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 241000192132 Leuconostoc Species 0.000 description 1
- 241000209510 Liliopsida Species 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 241001218993 Panagrolaimus superbus Species 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 108700020962 Peroxidase Proteins 0.000 description 1
- 231100000674 Phytotoxicity Toxicity 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000589180 Rhizobium Species 0.000 description 1
- 241000220010 Rhode Species 0.000 description 1
- 241000190932 Rhodopseudomonas Species 0.000 description 1
- 241000223252 Rhodotorula Species 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241000222068 Sporobolomyces <Sporidiobolaceae> Species 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 241000589500 Thermus aquaticus Species 0.000 description 1
- 241000589634 Xanthomonas Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 244000000060 biotrophic pathogen Species 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000004640 cellular pathway Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- LFHISGNCFUNFFM-UHFFFAOYSA-N chloropicrin Chemical compound [O-][N+](=O)C(Cl)(Cl)Cl LFHISGNCFUNFFM-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000012272 crop production Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- QAYICIQNSGETAS-UHFFFAOYSA-N dazomet Chemical compound CN1CSC(=S)N(C)C1 QAYICIQNSGETAS-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- WZRZTHMJPHPAMU-UHFFFAOYSA-L disodium;(3e)-3-[(4-amino-3-sulfonatophenyl)-(4-amino-3-sulfophenyl)methylidene]-6-imino-5-methylcyclohexa-1,4-diene-1-sulfonate Chemical compound [Na+].[Na+].C1=C(S([O-])(=O)=O)C(=N)C(C)=CC1=C(C=1C=C(C(N)=CC=1)S([O-])(=O)=O)C1=CC=C(N)C(S(O)(=O)=O)=C1 WZRZTHMJPHPAMU-UHFFFAOYSA-L 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000000835 effect on nematodes Effects 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 241001233957 eudicotyledons Species 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Substances NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000002316 fumigant Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 210000002980 germ line cell Anatomy 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 238000003505 heat denaturation Methods 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 238000005567 liquid scintillation counting Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 229940102396 methyl bromide Drugs 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000001069 nematicidal effect Effects 0.000 description 1
- 235000021231 nutrient uptake Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000017448 oviposition Effects 0.000 description 1
- 230000008186 parthenogenesis Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000361 pesticidal effect Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 230000003032 phytopathogenic effect Effects 0.000 description 1
- 244000000003 plant pathogen Species 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000032361 posttranscriptional gene silencing Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000001044 red dye Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000028710 ribosome assembly Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000021749 root development Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000000276 sedentary effect Effects 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000003584 silencer Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8261—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield
- C12N15/8271—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance
- C12N15/8279—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance
- C12N15/8285—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance for nematode resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43536—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
- C07K14/4354—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/10—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in agriculture
- Y02A40/146—Genetically Modified [GMO] plants, e.g. transgenic plants
Definitions
- Plant parasitic nematodes such as root-knot nematodes (Meloidogyne species) and cyst nematodes (Globodera and Heterodera), attack nearly every food crop, and are among the world's most damaging agricultural pests.
- root-knot nematodes parasitize more than 2,000 plant species from diverse plant families and represent a tremendous threat to crop production world-wide.
- biotrophic pathogens have evolved highly specialized and complex feeding relationships with their hosts.
- Nematodes cause millions of dollars of damage each year to turf grasses, ornamental plants, and food crops. Efforts to eliminate or minimize damage caused by nematodes in agricultural settings have typically involved the use of soil fumigation with materials such as chloropicrin, methyl bromide, and dazomet, which volatilize to spread the active ingredient throughout the soil. Such fumigation materials can be highly toxic and may create an environmental hazard. Various non-fumigant chemicals have also been used, but these too create serious environmental problems and can be highly toxic to humans.
- Avermectin B 2a is active against the root- knot nematode, Meloidogyne incognita. It is reported to be 10-30 times as potent as commercial contact nematicides when incorporated into soil at 0.16-0.25 kg/ha (Boyce Thompson Institute for Plant Research 58th Annual Report [1981]; Putter, I. et al.
- Avermectins Novel Insecticides, Acaracides, and Nematicides from a Soil Microorganism
- Avermectin B 2a is not toxic to tomatoes or cucumbers at rates of up to 10 kg/ha.
- Fatty acids are a class of natural compounds which occur abundantly in nature and which have interesting and valuable biological activities.
- Tarjan and Cheo (Tarjan, A.C., P.C. Cheo [1956] "Nematocidal Value of Some Fatty Acids," Bulletin 332, Contribution 884, Agricultural Experiment Station, University of Rhode Island, guitarist, 41 pp.) report the activity of certain fatty acids against nematodes.
- Sitaramaiah and Singh Sanaramaiah, K., R.S. Singh [1977] Indian J. Nematol 7:58-65
- Sitaramaiah and Singh (Sitaramaiah, K., R.S. Singh [1977] Indian J. Nematol 7:58-65) also examined the response of nematodes to fatty acids.
- RNAi double- stranded interfering RNA
- RNAi-mediated interference RNA-mediated interference
- RNAi Agrobacterium tumefaciens-mediated transformation of Arabidopsis thaliana
- Agrobacterium tumefaciens-mediated transformation of Arabidopsis thaliana Choang, C.-F. and E. M. Meyerowitz [2000] "Specific and heritable genetic interference by double-stranded RNA in Arabidopsis thaliana” Proc. Natl. Acad. Sci. USA 97:4985- 4990).
- Chuang et al. describe the construction of vectors delivering variable levels of RNAi targeted to each of four genes involved in floral development. Severity of abnormal flower development varied between transgenic lines. For one of the genes, AGAMOUS (AG), a strong correlation existed between declining accumulation of mRNA and increasingly severe phenotypes, suggesting that AG-specific endogenous mRNA is the target of RNAi.
- the subject invention provides novel methods and compositions for controlling nematodes. More specifically, the subject invention provides polynucleotide sequences that encode nematode genes, RNAi that selectively targets mRNA transcripts of these essential nematode genes, and methods of using these sequences in nematode control strategies. Such sequences for use according to the subject invention are summarized in Appendix 1. RNAi molecules disclosed herein can be used to inhibit the expression of one or more of these genes in nematodes. Brief Description of the Drawings
- Figure 1 Modular Binary Construct System (MBCS): A series of six, 8-base cutter restriction enzyme sites has been placed between the left and right Ti borders of a previously created kan R /tet R binary plasmid.
- MBCS Modular Binary Construct System
- Figure 2 An exemplary shuttle vector created for cloning of useful DNA fragments by containing the multi-cloning site (MCS) of a modified Bluescript plasmid flanked by 8-base restriction sites.
- MCS multi-cloning site
- Figure 3 An exemplary shuttle vector with exemplary inserts.
- Figure 4 A suggested RNAi binary vector with exemplary inserts.
- Figure 5 Exemplary selectable markers for MBCS.
- Figure 6 Exemplary scorable markers for MCBS.
- Figure 7 Exemplary RNAi binary vector.
- Figure 8 Exemplary RNAi shuttle vector.
- the subject invention provides novel methods and compositions for controlling nematodes. More specifically, the subject invention provides polynucleotide sequences and methods of using these sequences in nematode control strategies.
- a preferred method for controlling nematodes according to the subject invention provides materials and methods for controlling nematodes by using double-stranded interfering RNA (RNAi), or RNA-mediated interference (RNAi).
- RNAi double-stranded interfering RNA
- RNAi RNA-mediated interference
- RNAi molecules are provided which are useful in methods of killing nematodes and/or inhibiting their growth, development, parasitism or reproduction. RNAi molecules of the invention are also useful for the regulation of levels of specific mRNA in nematodes.
- dsRNA typically comprises a polynucleotide sequence identical to a target gene (or fragment thereof) linked directly, or indirectly, to a polynucleotide sequence complementary to the sequence of the target gene (or fragment thereof).
- the dsRNA may comprise a polynucleotide linker (stuffer) sequence of sufficient length to allow for the two polynucleotide sequences to fold over and hybridize to each other; however, a linker sequence is not necessary.
- the linker (stuffer) sequence is designed to separate the antisense and sense strands of RNAi significantly enough to limit the effects of steric hindrances and allow for the formation of dsRNA molecules.
- RNA containing a nucleotide sequence identical to a fragment of the target gene is preferred for inhibition; however, RNA sequences with insertions, deletions, and point mutations relative to the target sequence can also be used for inhibition.
- Sequence identity may optimized by sequence comparison and alignment algorithms known in the art (see Gribskov and Devereux, Sequence Analysis Primer, Stockton Press, 1991, and references cited therein) and calculating the percent difference between the nucleotide sequences by, for example, the Smith- Waterman algorithm as implemented in the BESTFIT software program using default parameters (e.g. , University of Wisconsin Genetic Computing Group).
- the duplex region of the RNA may be defined functionally as a nucleotide sequence that is capable of hybridizing with a fragment of the target gene transcript.
- RNA and the target gene are not required to practice the present invention.
- the invention has the advantage of being able to tolerate sequence variations that might be expected due to genetic mutation, strain polymorphism, or evolutionary divergence.
- RNA may be synthesized either in vivo or in vitro. Endogenous RNA polymerase of the cell may mediate transcription in vivo, or cloned RNA polymerase can be used for transcription in vivo or in vitro.
- a regulatory region e.g., promoter, enhancer, silencer, splice donor and acceptor, polyadenylation
- Inhibition may be targeted by specific transcription in an organ, tissue, or cell type; stimulation of an environmental condition (e.g., infection, stress, temperature, chemical inducers); and/or engineering transcription at a developmental stage or age.
- RNA strands may or may not be polyadenylated; the RNA strands may or may not be capable of being translated into a polypeptide by a cell's translational apparatus.
- RNA may be chemically or enzymatically synthesized by manual or automated reactions.
- the RNA may be synthesized by a cellular RNA polymerase or a bacteriophage RNA polymerase (e.g., T3, T7, SP6).
- a cellular RNA polymerase or a bacteriophage RNA polymerase e.g., T3, T7, SP6.
- T3, T7, SP6 bacteriophage RNA polymerase
- the RNA may be purified prior to introduction into the cell.
- RNA can be purified from a mixture by extraction with a solvent or resin, precipitation, electrophoresis, chromatography, or a combination thereof.
- the RNA may be used with no or a minimum of purification to avoid losses due to sample processing.
- the RNA may be dried for storage or dissolved in an aqueous solution.
- the solution may contain buffers or salts to promote annealing, and/or stabilization of the duplex strands.
- RNAi can be targeted to an entire polynucleotide sequence of a gene set forth herein.
- Preferred RNAi molecules of the instant invention are highly homologous or identical to the polynucleotides summarized in Appendix 1. The homology is preferably greater than 90% and is most preferably greater than 95%.
- Fragments of genes can also be targeted. These fragments are typically in the approximate size range of about 20 nucleotides. Thus, targeted fragments are preferably at least about 15 nucleotides. In certain embodiments, the gene fragment targeted by the RNAi molecule is about 20-25 nucleotides in length. However, other size ranges can also be used. For example, using a C. elegans microinjection assay, RNAi "fragments" of about 60 nucleotides with between 95 and 100% identity (to a nematode gene) were determined to cause excellent inhibition.
- RNAi molecules of the subject invention are not limited to those that are targeted to the full-length polynucleotide or gene.
- the nematode gene product can be inhibited with a RNAi molecule that is targeted to a portion or fragment of the exemplified polynucleotides; high homology (90-95%) or identity is also preferred, but not necessarily essential, for such applications.
- the polynucleotide sequences identified in Appendix A and shown in the Sequence ID listing are from genes encoding nematode proteins having the functions shown in Appendix 1.
- the genes exemplified herein are representative of particular classes of proteins which are preferred targets for disruption according to the subject invention. These classes of proteins include, for example, proteins involved in ribosome assembly; neurol transmitter receptors and ligands; electron transport proteins; metabolic pathway proteins; and protein and polynucleotide production, folding, and processing proteins.
- Genetic regulatory sequences such as promoters, enhancers, and terminators, can be used in genetic constructs to practice the subject invention. Such constructs themselves can also be used for nematode control. Various constructs can be used to achieve expression in specific plant tissues (by using root specific promoters, for example) and/or to target specific nematode tissues (by using targeting elements or adjacent targeting sequences, for example).
- plant cells are genetically modified to produce at least one RNAi that is designed to be taken up by nematodes during feeding to block expression (or the function of) of a target gene.
- RNAi can target and reduce (and, in some cases, prevent) the translation of a specific gene product.
- RNAi can be used to reduce or prevent message translation in any tissue of the nematode because of its ability to cross tissue and cellular boundaries.
- RNAi that is contacted with a nematode by soaking, injection, or consumption of a food source will cross tissue and cellular boundaries.
- RNAi can also be used as an epigenetic factor to prevent the proliferation of subsequent generations of nematodes.
- Nematode polynucleotide sequences disclosed herein demonstrate conserved nucleotide motifs among different nematode genera. conserveed nucleotide motifs strongly suggest that these sequences are associated with viability and/or parasitism and are functionally conserved and expressed in both Meloidogyne incognita (root-knot nematode) and Globodera rostochiensis and Globdera pallids (potato cyst nematodes).
- the use of these polynucleotides, and RNAi inhibitors thereof, is advantageous because such RNAi can be designed to have broad RNAi specificity and are thus useful for controlling a large number of plant parasitic nematodes in planta.
- RNAi inhibition of these genes prevents and/or reduces parasitic nematode growth, development, and or parasitism.
- Methods of the subject invention include the transformation of plant cells with genes or polynucleotides of the present invention, which can be used to produce nematode inhibitors or RNAi in the plants.
- the transformed plant or plant tissue can express RNAi molecules encoded by the gene or polynucleotide sequence introduced into the plant.
- Other nematode inhibitors contemplated by the invention include antisense molecules specific to the polynucleotide sequences disclosed herein.
- the transformation of plants with genetic constructs disclosed herein can be accomplished using techniques well known to those skilled in the art and can involve modification of the gene(s) to optimize expression in the plant to be made resistant to nematode infection and infestation.
- many tissues of the transgenic plants (such as the roots) can be targeted for transformation.
- RNA-mediated interference of gene expression.
- RNAi RNA-mediated interference
- C. elegans Several aspects of root-knot nematode biology make classical genetic studies difficult with this organism. Since root-knot nematodes reproduce by obligatory mitotic parthenogenesis, the opportunity to perform genetic crosses is not available.
- Microinjection of RNAi can be used to manipulate gene expression in C. elegans (Fire, A., S. Xu, M. K. Montgomery, S. A. Kostas, S. E. Driver, and C. C. Mello. [1998] "Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans" Nature 391 :806- 811).
- RNAi can turn off specific genes in progeny worms complementary to the coding region of the genes. Moreover, gene inhibition occurs in progeny when RNAi is injected into the body cavity of the adult, indicating the ability of the RNAi to cross cellular boundaries. This RNAi injection method provides a molecular genetic tool that allows for analysis of gene function in root-knot nematodes.
- RNAi can be taken up by C. elegans by simply soaking the nematodes in a solution RNAi. This results in targeted inhibition of gene expression in the nematode (Maeda, I., Y. Kohara, M. Yamamoto and A. Sugimoto [1999] "RNAi screening with a non-redundant cDNA set" International Worm Meeting, Madison, WI, abstract 565). Nematodes fed E. coli expressing RNAi also demonstrate targeted and heritable inhibition of gene expression (Sarkissian, M., H. Tabara and C. C.
- one aspect of the instant invention is directed to the control of nematodes comprising contacting nematodes with compositions comprising RNAi molecules specific to the nematode genes disclosed herein.
- the contacting step may include soaking the nematodes in a solution containing RNAi molecules, feeding nematodes RNAi molecules contained in microbes or plant cells upon which the nematode feeds, or injecting nematodes with RNAi.
- Nematodes can also be "contacted” and controlled by RNAi expressed in plant tissues that would be consumed, ingested, or frequented by nematodes.
- RNAi molecules provided to the nematodes may be specific to a single gene.
- a "cocktail” of RNAi molecules specific to various segments of a single gene can also be used.
- a "multigene cocktail” of RNAi molecules specific to two or more genes (or segments thereof) may be applied to the nematodes according to the subject invention.
- nematodes can be directly transformed with RNAi constructs of cDNAs encoding secretory or other essential proteins to reduce expression of the corresponding gene.
- the transgenic animals can be assayed for inhibition of gene product using immunoassays or for reduced virulence on a host. Progeny of affected worms can also be assayed by similar methods.
- RNAi Procedures that can be used for the preparation and injection of RNAi include those detailed by Fire et al, (1998; ftp://ciwl.ciwemb.edu).
- Root-knot nematodes can be routinely monoxenically cultured on Arabidopsis thaliana roots growing on Gamborg's B-5/Gelrite® media.
- This nematode-host pathosystem is ideally suited for these microinjection experiments since limited root galling results in the parasitic stages (late J2 through adult females) developing outside of the root for easy accessibility for injecting.
- Another advantage is the parthenogenic reproduction of root- knot nematodes, which makes fertilization by males unnecessary for egg production.
- RNAi can be injected into the body cavity of parasitic stages of root-knot nematodes feeding on A. thaliana roots using microinjection.
- Control nematodes can be injected in parallel with only buffer or an unrelated RNAi.
- Injected nematodes can be monitored for egg production, and the eggs can be collected for the assays described below.
- Female root-knot nematodes will typically survive and lay more than 250 eggs following 1 ⁇ l injection of buffer.
- RNAi molecules for efficacy by directly inhibiting growth and development of the nematode feeding upon the microinjected plant cell, or by reducing fecundity and the ability of said nematode to generate pathogenic or viable progeny.
- RNAi gene interference There are a number of strategies that can be followed to assay for RNAi gene interference. Inhibition of gene expression by RNAi inhibits the accumulation of the corresponding secretory protein in the esophageal gland cells of transgenic J2 hatched from the eggs produced by the injected nematodes.
- polyclonal antibodies to the target gene product can be used in immunolocalization studies (Hussey, R. S. [1989] "Monoclonal antibodies to secretory granules in esophageal glands of Meloidogyne species" J Nematol. 21:392-398; Borgonie, G, E. van Driessche, C. D. Link, D.
- Control nematodes injected only with the injection buffer can be processed similar to the RNAi treated nematodes.
- Another assay is designed to determine the effect of the RNAi on reducing the virulence of J2 progeny of the injected females.
- Egg masses from injected females can be transferred singly to A. thaliana plates to assess the ability of the transgenic J2 to infect roots.
- the J2 hatching from the eggs transferred to the plates can be monitored; after 25 days the number of galls with egg laying females can be recorded.
- the A. thaliana roots can also be stained with acid fuschin to enumerate the number of nematodes in the roots.
- Egg masses from nematodes injected only with the injection buffer can be handled similarly and used as controls. The treatments can be replicated, and the root infection data can be analyzed statistically. These experiments can be used to assess the importance of the target genes in root-knot nematode 's virulence or viability. By staining the J2 progeny of the injected females with the antibodies, it can be determined whether RNAi blocks expression of the targeted gene.
- polynucleotides can be used in a variety of ways. These polynucleotides can be used in assays for additional polynucleotides and additional homologous genes, and can be used in tracking the quantitative and temporal expression of parasitism genes in nematodes. These polynucleotides can be cloned into microbes for production and isolation of their gene products. Among the many uses of the isolated gene product is the development of additional inhibitors and modifiers. The protein products of the subject polynucleotides can also be used as diagnostic tools.
- proteins encoded by the parasitism genes, as identified herein can be used in large scale screenings for additional peptide inhibitors.
- the use of peptide phage display screening is one method that can be used in this regard.
- the subject invention also provides new biotechnological strategies for managing nematodes under sustainable agricultural conditions.
- Antisense technologies can also be used for phytopathogenic nematode control. Antisense technology can be used to interfere with expression of the disclosed endogenous nematode genes. Antisense technology can also be used to alter the components of plants used as targets by the nematodes. For example, the transformation of a plant with the reverse complement of an endogenous gene encoded by a polynucleotide exemplified herein can result in strand co-suppression and gene silencing or inhibition of a target involved in the nematode infection process.
- the subject invention includes transgenic plants (which are preferably made nematode-resistant in this manner, and other organisms including microbes and phages) comprising RNAi or antisense molecules specific to any of the polynucleotides identified herein.
- DNA possesses a fundamental property called base complementarity.
- base complementarity In nature, DNA ordinarily exists in the form of pairs of anti- parallel strands, the bases on each strand projecting from that strand toward the opposite strand.
- the base adenine (A) on one strand will always be opposed to the base thymine (T) on the other strand, and the base guanine (G) will be opposed to the base cytosine (C).
- the bases are held in apposition by their ability to hydrogen bond in this specific way. Though each individual bond is relatively weak, the net effect of many adjacent hydrogen bonded bases, together with base stacking effects, is a stable joining of the two complementary strands.
- hybridization can be highly specific. That is, only strands with a high degree of base complementarity will be able to form stable double-stranded structures.
- the relationship of the specificity of hybridization to reaction conditions is well known. Thus, hybridization may be used to test whether two pieces of DNA are complementary in their base sequences. It is this hybridization mechanism which facilitates the use of probes of the subject invention to readily detect and characterize DNA sequences of interest.
- the specifically exemplified polynucleotides of the subject invention can themselves be used as probes. Additional polynucleotide sequences can be added to the ends of (or internally in) the exemplified polynucleotide sequences so that polynucleotides that are longer than the exemplified polynucleotides can also be used as probes. Thus, isolated polynucleotides comprising one or more of the exemplified sequences are within the scope of the subject invention. Polynucleotides that have less nucleotides than the exemplified polynucleotides can also be used and are contemplated within the scope of the present invention.
- polynucleotides of the subject invention can be used to find additional, homologous (wholly or partially) genes.
- Probes of the subject invention may be composed of DNA, RNA, or PNA (peptide nucleic acid).
- the probe will normally have at least about 10 bases, more usually at least about 17 bases, and may have about 100 bases or more. Longer probes can readily be utilized, and such probes can be, for example, several kilobases in length.
- the probe sequence is designed to be at least substantially complementary to a portion of a gene encoding a protein of interest. The probe need not have perfect complementarity to the sequence to which it hybridizes.
- the probes may be labeled utilizing techniques that are well known to those skilled in this art.
- One approach for the use of the subject invention as probes entails first identifying DNA segments that are homologous with the disclosed nucleotide sequences using, for example, Southern blot analysis of a gene bank.
- Southern blot analysis of a gene bank.
- One hybridization procedure useful according to the subject invention typically includes the initial steps of isolating the DNA sample of interest and purifying it chemically. Either lysed nematodes or total fractionated nucleic acid isolated from nematodes can be used. Cells can be treated using known techniques to liberate their DNA (and/or RNA). The DNA sample can be cut into pieces with an appropriate restriction enzyme. The pieces can be separated by size through electrophoresis in a gel, usually agarose or acrylamide. The pieces of interest can be transferred to an immobilizing membrane.
- the particular hybridization technique is not essential to the subject invention. As improvements are made in hybridization techniques, they can be readily applied.
- the probe and sample can then be combined in a hybridization buffer solution and held at an appropriate temperature until annealing occurs. Thereafter, the membrane is washed free of extraneous materials, leaving the sample and bound probe molecules typically detected and quantified by autoradiography and/or liquid scintillation counting.
- the probe molecule and nucleic acid sample hybridize by forming a strong non-covalent bond between the two molecules, it can be reasonably assumed that the probe and sample are essentially identical or very similar.
- the probe's detectable label provides a means for determining in a known manner whether hybridization has occurred.
- the particular probe is labeled with any suitable label known to those skilled in the art, including radioactive and non-radioactive labels.
- Typical radioactive labels include 32 P, 35 S, or the like.
- Non- radioactive labels include, for example, ligands such as biotin or thyroxine, as well as enzymes such as hydrolases or peroxidases, or the various chemiluminescers such as luciferin, or fluorescent compounds like fluorescein and its derivatives.
- the probes can be made inherently fluorescent as described in International Application No. WO 93/16094.
- hybridization is conducted under moderate to high stringency conditions by techniques well known in the art, as described, for example, in Keller, G.H., M.M. Manak (1987) DNA Probes, Stockton Press, New York, NY., pp. 169-170.
- moderate to high stringency conditions for hybridization refers to conditions that achieve the same, or about the same, degree of specificity of hybridization as the conditions "as described herein.” Examples of moderate to high stringency conditions are provided herein. Specifically, hybridization of immobilized DNA on Southern blots with 32 P-labeled gene-specific probes was performed using standard methods (Maniatis et al). In general, hybridization and subsequent washes were carried out under moderate to high stringency conditions that allowed for detection of target sequences with homology to sequences exemplified herein.
- Tm 81.5°C+16.6 Log[Na+]+0.41(%G+C)-0.61(%formamide)- 600/length of duplex in base pairs.
- Washes are typically carried out as follows:
- Tm melting temperature
- Tm (°C) * 2(number T/A base pairs) +4(number G/C base pairs)
- salt and/or temperature can be altered to change stringency.
- salt and/or temperature can be altered to change stringency.
- Moderate 0.2X or IX SSPE, 65 °C High: 0.1X SSPE, 65°C.
- polynucleotide sequences of the subject invention include mutations (both single and multiple), deletions, and insertions in the described sequences, and combinations thereof, wherein said mutations, insertions, and deletions permit formation of stable hybrids with a target polynucleotide of interest. Mutations, insertions, and deletions can be produced in a given polynucleotide sequence using standard methods known in the art. Other methods may become known in the future.
- the mutational, insertional, and deletional variants of the polynucleotide sequences of the invention can be used in the same manner as the exemplified polynucleotide sequences so long as the variants have substantial sequence similarity with the original sequence.
- substantial sequence similarity refers to the extent of nucleotide similarity that is sufficient to enable the variant polynucleotide to function in the same capacity as the original sequence.
- this similarity is greater than 50%; more preferably, this similarity is greater than 75%; and most preferably, this similarity is greater than 90%.
- the degree of similarity needed for the variant to function in its intended capacity will depend upon the intended use of the sequence. It is well within the skill of a person trained in this art to make mutational, insertional, and deletional mutations that are designed to improve the function of the sequence or otherwise provide a methodological advantage.
- PCR Polymerase Chain Reaction
- PCR is a repetitive, enzymatic, primed synthesis of a nucleic acid sequence. This procedure is well known and commonly used by those skilled in this art (see U.S. Patent Nos. 4,683,195; 4,683,202; and 4,800,159; Saiki et al, 1985).
- PCR is based on the enzymatic amplification of a DNA fragment of interest that is flanked by two oligonucleotide primers that hybridize to opposite strands of the target sequence. The primers are oriented with the 3' ends pointing towards each other.
- thermostable DNA polymerase such as Taq polymerase, which is isolated from the thermophilic bacterium Thermus aquaticus, the amplification process can be completely automated.
- Other enzymes that can be used are known to those skilled in the art.
- polynucleotide sequences of the subject invention can be used as, and/or used in the design of, primers for PCR amplification.
- a certain degree of mismatch can be tolerated between primer and template. Therefore, mutations, deletions, and insertions (especially additions of nucleotides to the 5' end) of the exemplified ppolynucleotides can be used in this manner. Mutations, insertions and deletions can be produced in a given primer by methods known to an ordinarily skilled artisan.
- the polynucleotide sequences of the instant invention may be "operably linked” to regulatory sequences such as promoters and enhancers.
- Nucleic acid is “operably linked” when it is placed into a functional relationship with another nucleic acid sequence.
- DNA for a presequence or secretory leader is “operably linked” to DNA encoding a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide;
- a promoter or enhancer is “operably linked” to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is “operably linked” to a coding sequence if it is positioned so as to facilitate translation.
- operably linked means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice.
- Polynucleotides and proteins Polynucleotides and proteins.
- Polynucleotides of the subject invention can be defined according to several parameters. One characteristic is the biological activity of the protein products as identified herein.
- the proteins and genes of the subject invention can be further defined by their amino acid and nucleotide sequences.
- the sequences of the molecules can be defined in terms of homology to certain exemplified sequences as well as in terms of the ability to hybridize with, or be amplified by, certain exemplified probes and primers. Additional primers and probes can readily be constructed by those skilled in the art such that alternate polynucleotide sequences encoding the same amino acid sequences can be used to identify and/or characterize additional genes.
- the proteins of the subject invention can also be identified based on their immunoreactivity with certain antibodies.
- polynucleotides and proteins of the subject invention include portions, fragments, variants, and mutants of the full-length sequences as well as fusions and chimerics, so long as the encoded protein retains the characteristic biological activity of the proteins identified herein.
- variants or variantations refer to nucleotide sequences that encode the same proteins or which encode equivalent proteins having equivalent biological activity.
- equivalent proteins refers to proteins having the same or essentially the same biological activity as the exemplified proteins.
- genes within the scope of the subject invention can be identified and obtained through several means.
- the specific genes exemplified herein may be obtained from root-knot nematodes. Genes, or portions or variants thereof, may also be artificially synthesized by, for example, a gene synthesizer.
- genes may be readily constructed using standard techniques such as site-directed mutagenesis and other methods of making point mutations and by DNA shuffling, for example.
- gene and protein fragments can be made using commercially available exonucleases, endonucleases, and proteases according to standard procedures.
- enzymes such as E /31 can be used to systematically cut off nucleotides from the ends of genes.
- genes that encode fragments may be obtained using a variety of restriction enzymes. Proteases may be used to directly obtain active fragments of these proteins.
- molecular techniques for cloning polynucleotides and producing gene constructs of interest are also well known in the art. In vitro evaluation techniques, such as MAXYGEN's "Molecular Breeding" can also be applied to practice the subject invention.
- antibodies raised against proteins encoded by polynucleotides disclosed herein can be used to identify and isolate proteins from a mixture of proteins. Specifically, antibodies may be raised to the portions of the proteins that are conserved and most distinct from other proteins. These antibodies can then be used to specifically identify equivalent proteins by immunoprecipitation, enzyme linked immunosorbent assay (ELISA), or Western blotting.
- ELISA enzyme linked immunosorbent assay
- Antibodies to proteins encoded by polynucleotides disclosed herein, or to equivalent proteins can readily be prepared using standard procedures known in the art. The genes that encode these proteins can be obtained from various organisms.
- DNA sequences can encode the amino acid sequences encoded by the polynucleotide sequences disclosed herein. It is well within the skill of a person trained in the art to create these alternative DNA sequences encoding proteins having the same, or essentially the same, amino acid sequence. These variant DNA sequences are within the scope of the subject invention. As used herein, reference to "essentially the same" sequence refers to sequences that have amino acid substitutions, deletions, additions, or insertions that do not materially affect biological activity. Fragments retaining the characteristic biological activity are also included in this definition.
- a further method for identifying genes and polynucleotides (and the proteins encoded thereby) of the subject invention is through the use of oligonucleotide probes.
- Probes provide a rapid method for identifying genes of the subject invention.
- the nucleotide segments that are used as probes according to the invention can be synthesized using a DNA synthesizer and standard procedures.
- the subject invention comprises variant or equivalent proteins (and nucleotide sequences coding for equivalent proteins or for inhibitors of the genes encoding such proteins) having the same or similar biological activity of inhibitors or proteins encoded by the exemplified polynucleotides.
- Equivalent proteins will have amino acid similarity with an exemplified protein (or peptide).
- the amino acid and/or nucleotide identity will typically be greater than 60%.
- the identity will be greater than 75%. More preferably, the identity will be greater than 80%, and even more preferably greater than 90%. Most preferably, the identity will be greater than 95%.
- RNAi molecules will also have corresponding identities in these preferred ranges.
- amino acids may be placed in the following classes: non-polar, uncharged polar, basic, and acidic. Conservative substitutions whereby an amino acid of one class is replaced with another amino acid of the same type fall within the scope of the subject invention so long as the substitution does not materially alter the biological activity of the compound.
- non-conservative substitutions can also be made.
- the critical factor is that these substitutions must not detract from the ability to manage nematode-caused diseases.
- An "isolated” or “substantially pure” nucleic acid molecule or polynucleotide is a polynucleotide that is substantially separated from other polynucleotide sequences which naturally accompany a nucleic acid molecule.
- the term embraces a polynucleotide sequence which was removed from its naturally occurring environment by the hand of man. This includes recombinant or cloned DNA isolates, chemically synthesized analogues and analogues biologically synthesized by heterologous systems.
- An "isolated” or “purified” protein likewise, is a protein removed from its naturally occurring environment.
- RNAi polynucleotides within the scope of the present invention can be introduced into a wide variety of microbial or plant hosts. Plant cells can be transformed (made recombinant) in this manner. Microbes, for example, can also be used in the application of RNAi molecules of the subject invention in view of the fact that microbes are a food source for nematodes
- heterologous gene or polynucleotide there are many methods for introducing a heterologous gene or polynucleotide into a host cell or cells under conditions that allow for stable maintenance and expression of the gene or polynucleotide. These methods are well known to those skilled in the art.
- Synthetic genes such as, for example, those genes modified to enhance expression in a heterologous host (such as by preferred codon usage or by the use of adjoining, downstream, or upstream enhancers) that are functionally equivalent to the genes (and which encode equivalent proteins) can also be used to transform hosts. Methods for the production of synthetic genes are known in the art.
- the gene or polynucleotide of interest is introduced via a suitable vector into a microbial host, and said host is applied to the environment in a living state, certain host microbes are preferred.
- Certain microorganism hosts are known to occupy the phytosphere, phylloplane, phyllosphere, rhizosphere, and/or rhizoplane of one or more crops of interest. These microorganisms can be selected so as to be capable of successfully competing in the particular environment (crop and other habitats) with the wild-type microorganisms, provide for stable maintenance and expression of the gene expressing a polypeptide of interest, and, desirably, provide for improved protection of the protein/peptide from environmental degradation and inactivation.
- microorganisms A large number of microorganisms is known to inhabit the phylloplane (the surface of the plant leaves) and/or the rhizosphere (the soil surrounding plant roots) of a wide variety of important crops. These microorganisms include bacteria, algae, and fungi.
- microorganisms such as bacteria, e.g., genera Pseudomonas, Erwinia, Serratia, Klebsiella, Xanthomonas, Streptomyces, Rhizobium, Rhodopseudomonas, Methylophilius, Agrobacterium, Acetobacter, Lactobacillus, Arthrobacter, Azotobacter, Leuconostoc, and Alcaligenes; fungi, particularly yeast, e.g., genera Saccharomyces, Cryptococcus, Kluyveromyces, Sporobolomyces, Rhodotorula, and Aureobasidium.
- the pigmented microorganisms are particularly yeast.
- Methods of the subject invention also include the transformation of plants or plant tissue with genes which encode the RNAi molecules of the present invention.
- the transformed plant or plant tissue expresses antisense RNA and or RNAi. Transformation of cells can be made by those skilled in the art using standard techniques. Materials necessary for these transformations are disclosed herein or are otherwise readily available to the skilled artisan.
- RNAi molecules of the instant invention can be accomplished by a variety of additional methods that would be apparent to those skilled in the art having the benefit of the subject disclosure.
- a "cocktail" of two or more RNAi molecules can be used to disrupt one or more of the genes identified herein.
- the "cocktail” of RNAi molecules may be specific to segments of a single gene or the entire gene.
- a "multigene cocktail” of RNAi molecules specific to two or more genes (or segments thereof) is also encompassed by the instant invention.
- the disclosed RNAi molecules, cocktails, and/or multigene cocktails thereof may be used in conjunction with other known nematode control agents and methodologies. Such cocktails can be used to combat the development of resistance by nematodes to a certain inhibitor or inhibitors.
- compositions of the subject invention which comprise RNAi molecules and carriers can be applied, themselves, directly or indirectly, to locations frequented by, or expected to be frequented by, nematodes.
- Microbial hosts which were transformed with polynucleotides that encode RNAi molecules, express said RNAi molecules, and which colonize roots (e.g., Pseudomonas, Bacillus, and other genera) can be applied to the sites of the pest, where they will proliferate and be ingested. The result is control of the pest.
- methods of the subject invention include, for example, the application of recombinant microbes to the pests (or their locations).
- the recombinant microbes may also be transformed with more than one RNAi molecule thereby delivering a "cocktail" of RNAi molecules to the nematode pests.
- a carrier may be any substance suitable for delivering the RNAi molecules to the nematode. Acceptable carriers are well known in the art and also are commercially available. For example, such acceptable carriers are described in E.W. Martin's Remington's Pharmaceutical Science, Mack Publishing Company, Easton, PA.
- a hairy root assay system was developed for testing the anti-nematode activity of RNAi molecules.
- Agrobacterium rhizogenes Several Agrobacterium rhizogenes strains produce hairy roots on a variety of plant species. A. rhizogenes strains, A4, 15834, 8196 and LBA4404 demonstrate hairy root development on tomato and sugar beet, with A4 being the most efficient. The A. rhizogenes strain K599 demonstrated very efficient formation on transgenic soybean hairy roots and was also effective on sugar beet and Arabidopsis. However, stain K599 failed to produce hairy roots on tomato tissues possibly due to hyper-virulence.
- Hairy root production Transgenic hairy roots were identified by stable GUS expression in tomato, sugar beet, soybean and Arabidopsis.
- the construct pAKKHOl (pNOS / NPT-II / tNOS // pSU / GUS / tNOS) was used to produce hairy roots when transformed into A. rhizogenes strains A4 or K599. Transgenic roots were identified by GUS expression.
- Electro-competent Agrobacterium Protocol [00089] 1. Grow Agrobacterium overnight in 5 mis LB + antibiotics at 30°C on shaker (for Agrobacterium rhizogenes strain K599 no antibiotics are needed). [00090] 2. Use the 5 mis of overnight culture to inoculate 500 mis LB + antibiotics at 30°C on shaker. Grow overnight. [00091 ] 3. Add liquid culture in eight 50 ml polypropylene orange cap tubes. [00092] 4. Centrifuge 10 min., 4000 rpm, 4°C.
- Example 3 Protocol for Production of Transgenic Hairy Roots on Soybean
- Seed Sterilization Rinse the soybean seed with 70% ETOH for 2-5 min. Remove and add 20% Clorox and shake for 20-25 min. Rinse 3X with sterile water. Plate the seed, 5 seed per plate, onto l A MSB5 + 2% sucrose + 0.2% gel (referred to as Vi MSB5). Place seed into chamber at 25C, 16/8 photoperiod for 5-7 day (depending on genotype) germination period. After 1 week seedlings can be placed into cold room for longer storage if necessary (not to exceed 2 weeks).
- Agrobacterium Preparation For Agrobacterium rhizogenes strain K599, take a small sample from frozen glycerol into 25-50 ml of NZYM media with 50 mg/L kanamycin in a 125-250 ml Erlenmyer flask. Place onto shaker at 28-30 °C for 16 - 20 hours. Pour sample into centrifuge tube and centrifuge the bacterium at 4000 rpm for 10 min. Pour off supernatant and re-suspend the pellet with an equal volume of liquid V_ MSB5 + 200 ⁇ M acetosyringone. Use pipette to re-suspend the pellet and homogenize the sample (remove all clumps).
- O.D. To determine O.D., prepare a 1:10 dilution by putting 900 ⁇ l MSB5 into cuvette and add 100 ⁇ l of bacterial sample. Determine the O.D. 660 and calculate the volume needed to adjust (dilute) OD to approximately 0.2 for inoculation. Check final O.D.
- Roots should develop in approximately 2-3 weeks. The roots will form primarily from the cut vascular bundles with other roots developing from the small cuts on cotyledon surface. Remove roots (>lcm in length) and place onto replica media with transfers to fresh media every 2 weeks to prevent Agrobacterium overgrowth. After 6-8 weeks on selection the roots can be moved to media without kanamycin, however carbenicillin must remain in media for several months for continued suppression of Agrobacterium. At this stage roots can be used for testing RNAi for nematode control. Sterilized nematodes can be added and observed for RNAi affects.
- nematodes can be used in appropriate bioassays.
- Caenorhabditis elegans a bacterial feeding nematode
- plant parasitic nematodes can be used for bioassay purposes.
- plant parasitic nematodes include a migratory endo-parasite, Pratylenchus scribneri (lesion), and two sedentary endo-parasites, Meloidogyne javanica (root-knot) and Heterodera schachtii (cyst).
- RNAi vectors can be tested through expression of the RNAi in E. coli.
- C. elegans are fed E. coli and assayed for their growth by measuring growth of nematodes, production of eggs and viability of offspring.
- Another approach is to inject dsRNA directly into living nematodes.
- soaking nematodes in a solution of in vz ' tr ⁇ -prepared RNAi can quickly establish efficacy of treatment.
- P. scribneri The P. scribneri in vitro feeding assay uses a corn root exudate (CRE) as a feeding stimulus and both the red dye Amaranth or potassium, arsenate as feeding indicators. Feeding is confirmed after seven days by the presence of red stained intestinal cells in live worms exposed to the Amaranth or death of worms exposed to arsenate. This bioassay is used to test soluble toxins or RNAi.
- P. scribneri has also been cultured on wild type roots of corn, rice and Arabidopsis, and on A. rhizogenes-induced hairy roots of sugar beet and tomato. P. scribneri is very valuable in evaluating transgenic hairy roots because of the non-specific feeding of these worms.
- M javanica Nematode eggs are sterilized using bleach and are used to inoculate hairy roots expressing RNAi. Nematodes are assessed for their growth by measuring knots, egg masses or production of viable eggs. An alternative approach is to microinject dsRNA directly into root feeding sites or into living female nematodes.
- H schachtii Cultures of this nematode were maintained on sugar beets. Nematodes eggs are sterilized using bleach and used to inoculate hairy roots expressing RNAi. Nematodes can be assessed for their growth by measuring knots, egg masses or production of viable eggs.
- Modular Binary Construct System An important aspect of the subject disclosure is the Modular Binary Construct System.
- the MBCS eases the burden of construct development by creating modular pieces of DNA that can be easily added, removed, or replaced with the use of low frequency cutting restriction enzymes (8-base cutters). These constructs are useful for delivery of a variety of genes to plant cells and is not limited to the delivery of RNAi genes.
- 8-base cutters 8-base cutters
- kan R and tet R MCBS aids the testing of constructs using different strains of Agrobacterium rhizogenes in different plant species.
- a series of shuttle vectors were created that aid in the cloning of useful DNA fragments by containing the multi-cloning site (MCS) of a modified Bluescript plasmid flanked by 8- base restriction sites ( Figure 2). With six 8-base cutter sites, each site is, preferably, reserved for a particular function ( Figures 3 and 4). Because of the close proximity of the Eme I and Sgfl sites to the left and right border of the binary vector, these sites are, preferably, reserved for gene tagging and enhancer trap experiments.
- the Not I site is, preferably, reserved for plant selectable markers ( Figure 5).
- the Pac I site is reserved, preferably, for Plant Scorable Markers ( Figure 6).
- the Asc I site is, preferably, reserved for R ⁇ Ai experiments ( Figures 7 and 8), while the Sbfl site is, preferably, reserved for anti-nematode proteins.
- the restriction sites that are denoted in the Figures are, preferably, reserved for the denoted insertions; however, the MCBS binary and shuttle vectors do not require the restriction sites to contain these suggested inserts.
- Plant Selectable Markers for MBCS To further develop the MBCS, a series of plant selectable markers were added to the MBCS ( Figure 5). Plant selectable markers that were added to the MBCS include: p ⁇ OS/ ⁇ PT-II/t ⁇ OS (kan R ), p ⁇ OS/Bar/t ⁇ OS (basta R for dicots), pUBI/Intron-Bar/t ⁇ OS (basta 11 for monocots), and pUBI/Intron-PMI/t ⁇ OS (mannitol isomerase 11 ).
- Reporter Genes for MBCS Four exemplary reporter genes are used in the MBCS are provided in Figure 6 and Appendix 2. GUS, a nuclear localized GUS, GEP, and the anthocyanin transcriptional activator papIC genes into the MBCS.
- Promoters for MBCS We cloned several useful constitutive and nematode-inducible promoters ( Figures 6, 7 and Appendix 2). Constitutive promoters include the SuperUbiquitin promoter from pine (pSU) and two promoter regions from the Strawberry Banding Vein virus (pSBVj and pSBV 2 ). Seven nematode-inducible promoters from Arabidopsis were also been cloned.
- RNAi shuttle vector to be used is adapted from the Modular Binary Construct System (MBCS - See Example 5).
- RNAi shuttle vectors preferably comprise a promoter, intron, antisense RNAi, stuffer fragment, sense RNAi, and terminator (See Figures 7 and 8 and Appendix 2 for more details).
- the plant promoter can be constitutive, tissue-specific or nematode-inducible.
- the intron is necessary to eliminate expression in Agrobacterium.
- RNAi molecules comprise nematode-specific sequences and are disclosed herein. These genes are associated with pathogenesis, growth, or other cellular function in nematodes.
- An exemplary group of RNAi sequences for use in plant/nematode control may be based upon:
- RNAi constructs allow for the formation of dsRNA molecules (the sense and antisense strands join to form the dsRNA).
- the terminator sequence adds a poly-A tail for transcriptional termination.
- the RNAi shuttle vector can then be subcloned into the MBCS and transformed into Agrobacterium rhizogenes.
- RNAi vector once introduced into the MBCS can subsequently (as a binary vector) be transformed in A. rhizogenes using, for example, the electroporation protocol of Example 2. Once the A. rhizogenes is confirmed to contain the plasmid, it is then used in generating hairy roots (See Example 3). Using this protocol transgenic hairy roots expressing RNAi are isolated, cultured and tested.
- RNAi expressing hairy roots can be inoculated with sterilized nematodes. Infested hairy roots can be observed and the effect on nematodes determined.
- An alternative approach involves the microinjection of RNAi directly into root feeding sites (giant-cells for root- knot nematode, and syncytia for cyst nematodes) or into living female nematodes.
- One aspect of the subject invention is the transformation of plants with genes encoding proteins of the present invention. Transformation of plants as described herein can be used to improve the resistance of these plants to attack by the target pest.
- RNAi molecules as disclosed or suggested herein can be inserted into plant cells using a variety of techniques which are well known in the art.
- cloning vectors for example, pBR322, pUC series, M13mp series, pACYC184, pMON, etc.
- biolistics microparticle bombardment
- Agrobacterium tumefaciens ox Agrobacterium rhizogenes- mediated transformation
- electroporation as well as other possible methods.
- the genetically modified-cell(s) can be screened via a vector carried-selectable marker that confers on the transformed plant cells resistance to a biocide or an antibiotic, such as kanamycin, G418, bleomycin, hygromycin, chloramphenicol, or bialophos, inter alia.
- the transformed cell will be regenerated into a morphologically normal plant.
- the transgene(s) in the transgenic plant is relatively stable and can be inherited by progeny plants.
- a transformation event involves a germ line cell
- the inserted DNA an corresponding phenotypic trait(s) will be transmitted to progeny plants.
- Such plants can be grown in the normal manner and crossed with plants that have the same transformed hereditary factors or other hereditary factors.
- the resulting hybrid individuals have the corresponding phenotypic properties.
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001275474A AU2001275474A1 (en) | 2000-06-12 | 2001-06-12 | Materials and methods for the control of nematodes |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21091700P | 2000-06-12 | 2000-06-12 | |
US60/210,917 | 2000-06-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001096584A2 true WO2001096584A2 (en) | 2001-12-20 |
WO2001096584A3 WO2001096584A3 (en) | 2003-01-23 |
Family
ID=22784842
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/018911 WO2001096584A2 (en) | 2000-06-12 | 2001-06-12 | Materials and methods for the control of nematodes |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2001275474A1 (en) |
WO (1) | WO2001096584A2 (en) |
Cited By (355)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003070886A2 (en) * | 2002-02-20 | 2003-08-28 | Sirna Therapeutics, Inc. | Inhibition of protein tyrosine phosphatase type iva expression byshort interfering nucleic acid |
WO2003093475A1 (en) * | 2002-04-30 | 2003-11-13 | Genesis Research And Development Corporation Limited | Compositions and methods for the modification of gene expression_using the superubiquitin promoter from pinus radiata |
WO2003070918A3 (en) * | 2002-02-20 | 2004-07-08 | Ribozyme Pharm Inc | Rna interference by modified short interfering nucleic acid |
WO2005071091A1 (en) * | 2003-12-23 | 2005-08-04 | Bayer Cropscience Sa | Method for modifying gene expression of a phytopathogenic fungus |
WO2005082932A2 (en) * | 2004-02-24 | 2005-09-09 | Basf Plant Science Gmbh | Compositions and methods using rna interference for control of nematodes in plants |
EP1572902A2 (en) * | 2002-02-01 | 2005-09-14 | Ambion, Inc. | HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES |
WO2006020821A2 (en) | 2004-08-13 | 2006-02-23 | Basf Plant Science Gmbh | Compositions and methods using rna interference for control of nematodes |
US7022828B2 (en) | 2001-04-05 | 2006-04-04 | Sirna Theraputics, Inc. | siRNA treatment of diseases or conditions related to levels of IKK-gamma |
WO2006047495A2 (en) | 2004-10-21 | 2006-05-04 | Venganza Inc | Methods and materials for conferring resistance to pests and pathogens of plants |
WO2007104570A2 (en) * | 2006-03-16 | 2007-09-20 | Devgen N.V. | Nematode control |
WO2007117657A2 (en) | 2006-04-07 | 2007-10-18 | The Research Foundation Of State University Of New York | Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency |
US7294504B1 (en) | 2001-12-27 | 2007-11-13 | Allele Biotechnology & Pharmaceuticals, Inc. | Methods and compositions for DNA mediated gene silencing |
WO2008095910A1 (en) | 2007-02-08 | 2008-08-14 | Basf Plant Science Gmbh | Compositions and methods using rna interference of opr3-like gene for control of nematodes |
WO2008095886A1 (en) | 2007-02-06 | 2008-08-14 | Basf Plant Science Gmbh | Compositions and methods using rna interference for control of nematodes |
WO2008095970A1 (en) | 2007-02-09 | 2008-08-14 | Basf Plant Science Gmbh | Compositions and methods using rna interference of cdpk-like for control of nematodes |
WO2008118324A2 (en) | 2007-03-26 | 2008-10-02 | Macrogenics, Inc. | Composition and method of treating cancer with an anti-uroplakin ib antibody |
US7491805B2 (en) | 2001-05-18 | 2009-02-17 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
JP2009523018A (en) * | 2006-01-12 | 2009-06-18 | デブジェン エヌブイ | Method for controlling pests using RNAi |
JP2009523017A (en) * | 2006-01-12 | 2009-06-18 | デブジェン エヌブイ | Genetically modified plant system method for plant pests using RNAi |
US7576261B2 (en) | 2004-10-13 | 2009-08-18 | University Of Georgia Research Foundation, Inc. | Nematode resistant transgenic plants |
US7645734B2 (en) | 2003-05-19 | 2010-01-12 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for treating and preventing heart tissue degeneration and uses thereof |
US7659389B2 (en) | 2001-05-18 | 2010-02-09 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of MYC and/or MYB gene expression using short interfering nucleic acid (siNA) |
US7659390B2 (en) | 2002-02-20 | 2010-02-09 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of muscarinic colinergic receptor gene expression using short interfering nucleic acid (siNA) |
US7662952B2 (en) | 2002-02-20 | 2010-02-16 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acid (siNA) |
US7662951B2 (en) | 2000-08-30 | 2010-02-16 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA) |
US7667029B2 (en) | 2002-02-20 | 2010-02-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of checkpoint kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA) |
US7667030B2 (en) | 2002-02-20 | 2010-02-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA) |
US7678897B2 (en) | 2002-02-20 | 2010-03-16 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA) |
US7691999B2 (en) | 2002-02-20 | 2010-04-06 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of NOGO and NOGO receptor gene expression using short interfering nucleic acid (siNA) |
US7700760B2 (en) | 2002-02-20 | 2010-04-20 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA) |
WO2010046423A2 (en) | 2008-10-22 | 2010-04-29 | Basf Se | Use of sulfonylurea herbicides on cultivated plants |
WO2010046422A2 (en) | 2008-10-22 | 2010-04-29 | Basf Se | Use of auxin type herbicides on cultivated plants |
US7795422B2 (en) | 2002-02-20 | 2010-09-14 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA) |
WO2010106163A1 (en) | 2009-03-20 | 2010-09-23 | Basf Plant Science Company Gmbh | Nematode-resistant transgenic plants |
US7803984B2 (en) * | 2002-07-10 | 2010-09-28 | Kansas State University Research Foundation | Compositions and methods for controlling plant parasitic nematodes |
US7833992B2 (en) | 2001-05-18 | 2010-11-16 | Merck Sharpe & Dohme | Conjugates and compositions for cellular delivery |
US7858769B2 (en) | 2004-02-10 | 2010-12-28 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using multifunctional short interfering nucleic acid (multifunctional siNA) |
US7868159B2 (en) | 2005-06-23 | 2011-01-11 | Baylor College Of Medicine | Modulation of negative immune regulators and applications for immunotherapy |
US7868158B2 (en) | 2004-07-19 | 2011-01-11 | Baylor College Of Medicine | Modulation of cytokine signaling regulators and applications for immunotherapy |
US7888326B2 (en) | 2003-04-04 | 2011-02-15 | The Trustees Of Columbia University In The City Of New York | Methods for promoting apoptosis and treating tumor cells inhibiting the expression or function of the transcription factor ATF5 |
US7893248B2 (en) | 2002-02-20 | 2011-02-22 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA) |
US7897752B2 (en) | 2002-02-20 | 2011-03-01 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of telomerase gene expression using short interfering nucleic acid (siNA) |
US7897757B2 (en) | 2002-02-20 | 2011-03-01 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA) |
US7897753B2 (en) | 2002-02-20 | 2011-03-01 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of XIAP gene expression using short interfering nucleic acid (siNA) |
US7910724B2 (en) | 2002-02-20 | 2011-03-22 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of Fos gene expression using short interfering nucleic acid (siNA) |
US7910725B2 (en) | 2002-02-20 | 2011-03-22 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA) |
US7915400B2 (en) | 2002-02-20 | 2011-03-29 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (siNA) |
US7923549B2 (en) | 2002-02-20 | 2011-04-12 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA) |
US7928220B2 (en) | 2002-02-20 | 2011-04-19 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of stromal cell-derived factor-1 (SDF-1) gene expression using short interfering nucleic acid (siNA) |
US7928219B2 (en) | 2002-02-20 | 2011-04-19 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (SINA) |
US7935812B2 (en) | 2002-02-20 | 2011-05-03 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA) |
US7943757B2 (en) | 2002-02-20 | 2011-05-17 | Mcswiggen James | RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA) |
WO2011062962A2 (en) | 2009-11-17 | 2011-05-26 | The Trustees Of The University Of Pennsylvania | Smndelta7 degron: novel compositions and methods of use |
US7977472B2 (en) | 2002-02-20 | 2011-07-12 | Leonid Beigelman | RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA) |
US7985853B2 (en) | 2002-02-20 | 2011-07-26 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of platelet derived growth factor (PDGF) and platelet derived growth factor receptor (PDGFR) gene expression using short interfering nucleic acid (siNA) |
US8008473B2 (en) | 2002-02-20 | 2011-08-30 | Mcswiggen James | RNA interference mediated inhibition of TNF and TNF receptor gene expression using short interfering nucleic acid (siNA) |
US8008472B2 (en) | 2001-05-29 | 2011-08-30 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA) |
WO2011104153A1 (en) | 2010-02-23 | 2011-09-01 | Basf Plant Science Company Gmbh | Nematode-resistant transgenic plants |
US8013143B2 (en) | 2002-02-20 | 2011-09-06 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of CXCR4 gene expression using short interfering nucleic acid (siNA) |
US8017761B2 (en) | 2001-05-18 | 2011-09-13 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of Stearoyl-CoA desaturase (SCD) gene expression using short interfering nucelic acid (siNA) |
EP2221377B1 (en) † | 2002-02-01 | 2011-10-19 | Life Technologies Corporation | Oligonucleotide compositions with enhanced efficiency |
US8067575B2 (en) | 2002-02-20 | 2011-11-29 | Merck, Sharp & Dohme Corp. | RNA interference mediated inhibition of cyclin D1 gene expression using short interfering nucleic acid (siNA) |
WO2012003207A3 (en) * | 2010-07-01 | 2012-02-16 | E. I. Du Pont De Nemours And Company | Plant seeds with altered storage compound levels, related constructs and methods involving genes encoding pae and pae-like polypeptides |
WO2012079000A1 (en) | 2010-12-09 | 2012-06-14 | The Trustees Of The University Of Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
US8221740B2 (en) | 2005-09-26 | 2012-07-17 | The Trustees Of Columbia University In The City Of New York | Side population cells in cardiac repair |
US8258288B2 (en) | 2002-02-20 | 2012-09-04 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of respiratory syncytial virus (RSV) expression using short interfering nucleic acid (siNA) |
EP2500429A2 (en) | 2005-05-31 | 2012-09-19 | Devgen N.V. | RNAi for the control of insects and arachnids |
US8324369B2 (en) | 2007-11-30 | 2012-12-04 | Baylor College Of Medicine | Dendritic cell vaccine compositions and uses of same |
WO2013050410A1 (en) | 2011-10-04 | 2013-04-11 | Bayer Intellectual Property Gmbh | RNAi FOR THE CONTROL OF FUNGI AND OOMYCETES BY INHIBITING SACCHAROPINE DEHYDROGENASE GENE |
WO2013055420A2 (en) | 2011-07-12 | 2013-04-18 | Philadelphia Health & Education Corporation | Novel clostridium difficile dna vaccine |
WO2013067492A1 (en) | 2011-11-03 | 2013-05-10 | The Trustees Of The University Of Pennsylvania | Isolated b7-h4 specific compositions and methods of use thereof |
WO2013078230A1 (en) | 2011-11-23 | 2013-05-30 | The Trustees Of The University Of Pennsylvania | Use of pdl1 expressing cells to convert t cells into regulatory t cells |
WO2013126729A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Use of the cd2 signaling domain in second-generation chimeric antigen receptors |
WO2013126733A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of University Of Pennsylvania | Use of icos-based cars to enhance antitumor activity and car persistence |
WO2014053395A1 (en) | 2012-10-01 | 2014-04-10 | Basf Se | Use of n-thio-anthranilamide compounds on cultivated plants |
WO2014090765A1 (en) | 2012-12-12 | 2014-06-19 | Bayer Cropscience Ag | Use of 1-[2-fluoro-4-methyl-5-(2,2,2-trifluoroethylsulfinyl)phenyl]-5-amino-3-trifluoromethyl)-1 h-1,2,4 tfia zole for controlling nematodes in nematode-resistant crops |
WO2014130635A1 (en) | 2013-02-20 | 2014-08-28 | Novartis Ag | Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells |
WO2014130657A1 (en) | 2013-02-20 | 2014-08-28 | The Trustees Of The University Of Pennsylvania | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor |
WO2014153270A1 (en) | 2013-03-16 | 2014-09-25 | Novartis Ag | Treatment of cancer using humanized anti-cd19 chimeric antigen receptor |
US8865968B2 (en) | 2004-10-04 | 2014-10-21 | Devgen Nv | Method for down-regulating gene expression in fungi |
US8957044B2 (en) | 2013-03-01 | 2015-02-17 | Wake Forest University Health Sciences | Systemic gene replacement therapy for treatment of X-linked myotubular myopathy (XLMTM) |
US8999654B2 (en) | 2002-09-09 | 2015-04-07 | Omeros Corporation | Method of identifying a compound for the treatment or prevention of obesity |
US9044461B2 (en) | 2006-04-07 | 2015-06-02 | The Research Foundation Of State University Of New York | Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency |
WO2015090230A1 (en) | 2013-12-19 | 2015-06-25 | Novartis Ag | Human mesothelin chimeric antigen receptors and uses thereof |
WO2015090229A1 (en) | 2013-12-20 | 2015-06-25 | Novartis Ag | Regulatable chimeric antigen receptor |
WO2015112626A1 (en) | 2014-01-21 | 2015-07-30 | June Carl H | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules |
WO2015116178A1 (en) | 2014-01-31 | 2015-08-06 | Thomas Jefferson University | Fusion proteins for modulating regulatory and effector t cells |
WO2015142675A2 (en) | 2014-03-15 | 2015-09-24 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
WO2015157252A1 (en) | 2014-04-07 | 2015-10-15 | BROGDON, Jennifer | Treatment of cancer using anti-cd19 chimeric antigen receptor |
WO2015168613A2 (en) | 2014-05-02 | 2015-11-05 | The Trustees Of The University Of Pennsylvania | Compositions and methods of chimeric autoantibody receptor t cells |
US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
WO2016011432A2 (en) | 2014-07-17 | 2016-01-21 | Czerniecki Brian J | Identification of immunogenic mhc class ii peptides for immune-based therapy |
WO2016014565A2 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Treatment of cancer using humanized anti-bcma chimeric antigen receptor |
WO2016014530A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Combinations of low, immune enhancing. doses of mtor inhibitors and cars |
WO2016014553A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
US9260471B2 (en) | 2010-10-29 | 2016-02-16 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) |
WO2016025880A1 (en) | 2014-08-14 | 2016-02-18 | Novartis Ag | Treatment of cancer using gfr alpha-4 chimeric antigen receptor |
US9267145B2 (en) | 2002-05-03 | 2016-02-23 | Duke University | Method of regulating gene expression |
US9272002B2 (en) | 2011-10-28 | 2016-03-01 | The Trustees Of The University Of Pennsylvania | Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting |
WO2016044605A1 (en) | 2014-09-17 | 2016-03-24 | Beatty, Gregory | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
WO2016057705A1 (en) | 2014-10-08 | 2016-04-14 | Novartis Ag | Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof |
WO2016090034A2 (en) | 2014-12-03 | 2016-06-09 | Novartis Ag | Methods for b cell preconditioning in car therapy |
US9365641B2 (en) | 2012-10-01 | 2016-06-14 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeting stromal cells for the treatment of cancer |
WO2016091674A1 (en) | 2014-12-12 | 2016-06-16 | Basf Se | Use of cyclaniliprole on cultivated plants |
WO2016098078A2 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Dimerization switches and uses thereof |
US9402865B2 (en) | 2011-01-18 | 2016-08-02 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating cancer |
WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
WO2016138491A1 (en) | 2015-02-27 | 2016-09-01 | Icell Gene Therapeutics Llc | Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof |
WO2016140910A2 (en) | 2015-03-04 | 2016-09-09 | University Of Rochester | Compositions and methods of using anti-mullerian hormone for treatment of infertility |
US9446105B2 (en) | 2013-03-15 | 2016-09-20 | The Trustees Of The University Of Pennsylvania | Chimeric antigen receptor specific for folate receptor β |
WO2016164308A1 (en) | 2015-04-06 | 2016-10-13 | Subdomain, Llc | De novo binding domain containing polypeptides and uses thereof |
WO2016164580A1 (en) | 2015-04-07 | 2016-10-13 | Novartis Ag | Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives |
WO2016164731A2 (en) | 2015-04-08 | 2016-10-13 | Novartis Ag | Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell |
WO2016162371A1 (en) | 2015-04-07 | 2016-10-13 | Basf Agrochemical Products B.V. | Use of an insecticidal carboxamide compound against pests on cultivated plants |
WO2016168595A1 (en) | 2015-04-17 | 2016-10-20 | Barrett David Maxwell | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
WO2016172583A1 (en) | 2015-04-23 | 2016-10-27 | Novartis Ag | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
WO2016170484A1 (en) | 2015-04-21 | 2016-10-27 | Novartis Ag | Rna-guided gene editing system and uses thereof |
WO2016174652A1 (en) | 2015-04-30 | 2016-11-03 | Technion Research & Development Foundation Limited | Chimeric antigen receptors and methods of their use |
WO2016178996A1 (en) | 2015-05-01 | 2016-11-10 | The Regents Of The University Of California | Glycan-dependent immunotherapeutic molecules |
WO2016187349A1 (en) | 2015-05-18 | 2016-11-24 | Tcr2, Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
WO2016210293A1 (en) | 2015-06-25 | 2016-12-29 | Icell Gene Therapeutics Llc | CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS OF USE THEREOF |
WO2017009853A1 (en) | 2015-07-16 | 2017-01-19 | Yeda Research And Development Co. Ltd. | Genetically modified anti-third party central memory t cells and use of same in immunotherapy |
WO2017015427A1 (en) | 2015-07-21 | 2017-01-26 | Novartis Ag | Methods for improving the efficacy and expansion of immune cells |
US9572836B2 (en) | 2012-07-13 | 2017-02-21 | The Trustees Of The University Of Pennsylvania | Methods for assessing the suitability of transduced T cells for administration |
WO2017040195A1 (en) | 2015-08-28 | 2017-03-09 | The Trustees Of The University Of Pennsylvania | Methods and compositions for cells expressing a chimeric intracellular signaling molecule |
WO2017040930A2 (en) | 2015-09-03 | 2017-03-09 | The Trustees Of The University Of Pennsylvania | Biomarkers predictive of cytokine release syndrome |
US9598489B2 (en) | 2012-10-05 | 2017-03-21 | The Trustees Of The Univeristy Of Pennsylvania | Human alpha-folate receptor chimeric antigen receptor |
WO2017070608A1 (en) | 2015-10-23 | 2017-04-27 | Eureka Therapeutics, Inc. | Antibody/t-cell receptor chimeric constructs and uses thereof |
WO2017075421A1 (en) | 2015-10-29 | 2017-05-04 | Temple University-Of The Commonwealth System Of Higher Education | Modification of 3' terminal ends of nucleic acids by dna polymerase theta |
US9657294B2 (en) | 2002-02-20 | 2017-05-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
WO2017088012A1 (en) | 2015-11-27 | 2017-06-01 | Cartherics Pty. Ltd. | Genetically modified cells and uses thereof |
WO2017095823A1 (en) | 2015-11-30 | 2017-06-08 | The Regents Of The University Of California | Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen |
WO2017112741A1 (en) | 2015-12-22 | 2017-06-29 | Novartis Ag | Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy |
WO2017117112A1 (en) | 2015-12-28 | 2017-07-06 | Novartis Ag | Methods of making chimeric antigen receptor -expressing cells |
WO2017118726A1 (en) | 2016-01-06 | 2017-07-13 | Lonza Ltd | Inhibition of protein degradation for improved production |
US9708384B2 (en) | 2011-09-22 | 2017-07-18 | The Trustees Of The University Of Pennsylvania | Universal immune receptor expressed by T cells for the targeting of diverse and multiple antigens |
WO2017149515A1 (en) | 2016-03-04 | 2017-09-08 | Novartis Ag | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore |
US9765156B2 (en) | 2012-07-13 | 2017-09-19 | The Trustees Of The University Of Pennsylvania | Enhancing activity of CAR T cells by co-introducing a bispecific antibody |
WO2017172981A2 (en) | 2016-03-29 | 2017-10-05 | University Of Southern California | Chimeric antigen receptors targeting cancer |
US9790267B2 (en) | 2011-11-08 | 2017-10-17 | The Trustees Of The University Of Pennsylvania | Glypican-3-specific antibody and uses thereof |
WO2017181101A1 (en) | 2016-04-15 | 2017-10-19 | The Trustees Of The University Of Pennsylvania | Compositions and methods of chimeric alloantigen receptor t cells |
WO2017178526A1 (en) | 2016-04-14 | 2017-10-19 | Lonza Ltd | Compositions and methods for the detection of host cell proteins |
WO2017181119A2 (en) | 2016-04-15 | 2017-10-19 | Novartis Ag | Compositions and methods for selective protein expression |
WO2017190001A1 (en) | 2016-04-29 | 2017-11-02 | The Regents Of The University Of Colorado, A Body Corporate | Compounds and compositions useful for treating metabolic syndrome, and methods using same |
US9808504B2 (en) | 2009-09-22 | 2017-11-07 | Yale University | Immunogenic epitopes as targets for universal cancer vaccines |
WO2017191165A1 (en) | 2016-05-03 | 2017-11-09 | Lonza Ltd | Modulation of lipid metabolism for protein production |
US9834612B2 (en) | 2011-07-22 | 2017-12-05 | The Research Foundation Of State University Of New York | Antibodies to the B12-transcobalamin receptor |
US9834610B2 (en) | 2013-01-31 | 2017-12-05 | Thomas Jefferson University | Fusion proteins for modulating regulatory and effector T cells |
WO2017210617A2 (en) | 2016-06-02 | 2017-12-07 | Porter, David, L. | Therapeutic regimens for chimeric antigen receptor (car)- expressing cells |
WO2017214333A1 (en) | 2016-06-08 | 2017-12-14 | Intrexon Corporation | Cd33 specific chimeric antigen receptors |
WO2018013918A2 (en) | 2016-07-15 | 2018-01-18 | Novartis Ag | Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor |
WO2018014122A1 (en) | 2016-07-18 | 2018-01-25 | Helix Biopharma Corp. | Car immune cells directed to carcinoembryonic antigen related cell adhesion molecule 6 to treat cancer |
WO2018023025A1 (en) | 2016-07-28 | 2018-02-01 | Novartis Ag | Combination therapies of chimeric antigen receptors adn pd-1 inhibitors |
WO2018026953A1 (en) | 2016-08-02 | 2018-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
WO2018026956A1 (en) | 2016-08-02 | 2018-02-08 | Lonza Ltd | Method and system for providing buffer solutions |
WO2018026819A2 (en) | 2016-08-01 | 2018-02-08 | Novartis Ag | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule |
WO2018031858A1 (en) | 2016-08-12 | 2018-02-15 | Lonza Ltd | Proteomic analysis of host cell proteins |
WO2018053542A1 (en) | 2016-09-19 | 2018-03-22 | University Of Southern California | Non-radioactive cytotoxicity assays |
US9937205B2 (en) | 2012-09-04 | 2018-04-10 | The Trustees Of The University Of Pennsylvania | Inhibition of diacylglycerol kinase to augment adoptive T cell transfer |
WO2018067992A1 (en) | 2016-10-07 | 2018-04-12 | Novartis Ag | Chimeric antigen receptors for the treatment of cancer |
WO2018067697A1 (en) | 2016-10-04 | 2018-04-12 | Precision Biosciences, Inc. | Co-stimulatory domains for use in genetically-modified cells |
WO2018067993A1 (en) | 2016-10-07 | 2018-04-12 | TCR2 Therapeutics Inc. | Compositions and methods for t-cell receptors reprogramming using fusion proteins |
US9944713B2 (en) | 2004-11-24 | 2018-04-17 | Medicinal Bioconvergence Research Center | Antibody specific to the AIMP2-DX2 |
WO2018083606A1 (en) | 2016-11-01 | 2018-05-11 | Novartis Ag | Methods and compositions for enhancing gene editing |
WO2018098365A2 (en) | 2016-11-22 | 2018-05-31 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
US9994853B2 (en) | 2001-05-18 | 2018-06-12 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
WO2018119298A1 (en) | 2016-12-21 | 2018-06-28 | TCR2 Therapeutics Inc. | Engineered t cells for the treatment of cancer |
US10011658B2 (en) | 2015-04-03 | 2018-07-03 | Eureka Therapeutics, Inc. | Constructs targeting AFP peptide/MHC complexes and uses thereof |
EP3346001A1 (en) | 2017-01-06 | 2018-07-11 | TXCell | Monospecific regulatory t cell population with cytotoxicity for b cells |
WO2018127585A1 (en) | 2017-01-06 | 2018-07-12 | Txcell | Monospecific regulatory t cell population with cytotoxicity for b cells |
WO2018132390A1 (en) | 2017-01-10 | 2018-07-19 | Christiana Care Health Services, Inc. | Methods for in vitro site-directed mutagenesis using gene editing technologies |
WO2018132494A1 (en) | 2017-01-10 | 2018-07-19 | Intrexon Corporation | Modulating expression of polypeptides via new gene switch expression systems |
WO2018134824A1 (en) | 2017-01-18 | 2018-07-26 | Yeda Research And Development Co. Ltd. | Genetically modified veto cells and use of same in immunotherapy |
WO2018140725A1 (en) | 2017-01-26 | 2018-08-02 | Novartis Ag | Cd28 compositions and methods for chimeric antigen receptor therapy |
US10040846B2 (en) | 2012-02-22 | 2018-08-07 | The Trustees Of The University Of Pennsylvania | Compositions and methods for generating a persisting population of T cells useful for the treatment of cancer |
WO2018145649A1 (en) | 2017-02-08 | 2018-08-16 | 西比曼生物科技(上海)有限公司 | Construction of chimeric antigen receptor targeting cd20 antigen and activity identification of engineered t cells thereof |
WO2018157072A1 (en) | 2017-02-27 | 2018-08-30 | Life Technologies Corporation | Expansion of populations of t cells by the use of modified serum free media |
US10066023B2 (en) | 2015-10-30 | 2018-09-04 | Aleta Biotherapeutics Inc. | Compositions and methods for tumor transduction |
US10106793B2 (en) | 2002-02-01 | 2018-10-23 | Life Technologies Corporation | Double-stranded oligonucleotides |
WO2018201056A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
WO2018200583A1 (en) | 2017-04-26 | 2018-11-01 | Eureka Therapeutics, Inc. | Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof |
WO2018208837A1 (en) | 2017-05-08 | 2018-11-15 | Precision Biosciences, Inc. | Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof |
WO2018232265A1 (en) | 2017-06-16 | 2018-12-20 | Lonza Ltd | Universal self-regulating mammalian cell line platform for the production of biologics |
WO2018232020A1 (en) | 2017-06-13 | 2018-12-20 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
WO2019007991A1 (en) | 2017-07-03 | 2019-01-10 | Universite De Strasbourg | Mtmr2-s polypeptide for use in the treatment of myopathies |
WO2019047899A1 (en) | 2017-09-06 | 2019-03-14 | 亘喜生物科技(上海)有限公司 | Universal chimeric antigen receptor t-cell preparation technique |
WO2019055853A1 (en) | 2017-09-15 | 2019-03-21 | Life Technologies Corporation | Compositions and methods for culturing and expanding cells |
WO2019062817A1 (en) | 2017-09-27 | 2019-04-04 | 亘喜生物科技(上海)有限公司 | Engineered immune cell capable of inducing secretion of anti-cd47 antibody |
WO2019070161A2 (en) | 2017-10-04 | 2019-04-11 | Opko Pharmaceuticals, Llc | Articles and methods directed to personalized therapy of cancer |
WO2019070856A1 (en) | 2017-10-03 | 2019-04-11 | Precision Biosciences, Inc. | Modified epidermal growth factor receptor peptides for use in genetically-modified cells |
WO2019069125A1 (en) | 2017-10-06 | 2019-04-11 | Oslo Universitetssykehus Hf | Chimeric antigen receptors |
WO2019084288A1 (en) | 2017-10-25 | 2019-05-02 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
WO2019089798A1 (en) | 2017-10-31 | 2019-05-09 | Novartis Ag | Anti-car compositions and methods |
WO2019092251A1 (en) | 2017-11-11 | 2019-05-16 | Universite De Strasbourg | Compositions and method for the treatment of x-linked centronuclear myopathy |
WO2019099639A1 (en) | 2017-11-15 | 2019-05-23 | Navartis Ag | Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies |
WO2019099440A1 (en) | 2017-11-14 | 2019-05-23 | Arcellx, Inc. | Multifunctional immune cell therapies |
WO2019099433A2 (en) | 2017-11-14 | 2019-05-23 | Arcellx, Inc. | D-domain containing polypeptides and uses thereof |
WO2019108900A1 (en) | 2017-11-30 | 2019-06-06 | Novartis Ag | Bcma-targeting chimeric antigen receptor, and uses thereof |
WO2019113050A1 (en) | 2017-12-05 | 2019-06-13 | Lonza Ltd | Methods of assaying tropolone |
WO2019129851A1 (en) | 2017-12-29 | 2019-07-04 | Cellectis | Method for improving production of car t cells |
WO2019136432A1 (en) | 2018-01-08 | 2019-07-11 | Novartis Ag | Immune-enhancing rnas for combination with chimeric antigen receptor therapy |
WO2019145711A1 (en) | 2018-01-23 | 2019-08-01 | Immetacyte Limited | Biomarker predictive of tumour infiltrating lymphocyte therapy and uses thereof |
WO2019152660A1 (en) | 2018-01-31 | 2019-08-08 | Novartis Ag | Combination therapy using a chimeric antigen receptor |
WO2019152876A2 (en) | 2018-02-02 | 2019-08-08 | Lonza Ltd | Methods of cell selection and modifying cell metabolism |
WO2019160956A1 (en) | 2018-02-13 | 2019-08-22 | Novartis Ag | Chimeric antigen receptor therapy in combination with il-15r and il15 |
EP3549611A1 (en) | 2011-07-29 | 2019-10-09 | The Trustees of the University of Pennsylvania | Switch costimulatory receptors |
WO2019196713A1 (en) | 2018-04-12 | 2019-10-17 | 西比曼生物科技(香港)有限公司 | Bcma-targeted chimeric antigen receptor as well as preparation method therefor and application thereof |
WO2019210153A1 (en) | 2018-04-27 | 2019-10-31 | Novartis Ag | Car t cell therapies with enhanced efficacy |
WO2019213282A1 (en) | 2018-05-01 | 2019-11-07 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
WO2019213180A1 (en) | 2018-04-30 | 2019-11-07 | Amicus Therapeutics, Inc. | Gene therapy constructs and methods of use |
WO2019217512A1 (en) | 2018-05-08 | 2019-11-14 | Life Technologies Corporation | Compositions and methods for culturing and expanding cells |
WO2019227003A1 (en) | 2018-05-25 | 2019-11-28 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
US10508143B1 (en) | 2015-10-30 | 2019-12-17 | Aleta Biotherapeutics Inc. | Compositions and methods for treatment of cancer |
US10508277B2 (en) | 2004-05-24 | 2019-12-17 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
WO2019241549A1 (en) | 2018-06-15 | 2019-12-19 | A2 Biotherapeutics, Inc. | Foxp3-expressing car-t regulatory cells |
WO2019241426A1 (en) | 2018-06-13 | 2019-12-19 | Novartis Ag | Bcma chimeric antigen receptors and uses thereof |
WO2019243835A1 (en) | 2018-06-21 | 2019-12-26 | Immetacyte Limited | Chimeric growth factor receptors |
WO2020030979A2 (en) | 2018-08-10 | 2020-02-13 | Sangamo Therapeutics France | New car constructs comprising tnfr2 domains |
WO2020047501A1 (en) | 2018-08-30 | 2020-03-05 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
WO2020047449A2 (en) | 2018-08-31 | 2020-03-05 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
WO2020047452A2 (en) | 2018-08-31 | 2020-03-05 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
WO2020043899A1 (en) | 2018-08-31 | 2020-03-05 | Invectys | Chimeric antigen receptors against multiple hla-g isoforms |
EP3623380A1 (en) | 2013-03-15 | 2020-03-18 | Michael C. Milone | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
WO2020069405A1 (en) | 2018-09-28 | 2020-04-02 | Novartis Ag | Cd22 chimeric antigen receptor (car) therapies |
WO2020069409A1 (en) | 2018-09-28 | 2020-04-02 | Novartis Ag | Cd19 chimeric antigen receptor (car) and cd22 car combination therapies |
WO2020077114A2 (en) | 2018-10-10 | 2020-04-16 | Amicus Therapeutics, Inc. | Disulfide bond stabilized polypeptide compositions and methods of use |
WO2020081929A1 (en) | 2018-10-19 | 2020-04-23 | University Of Rochester | Immune modulators in combination with radiation treatment for advanced pancreatic cancer |
WO2020086627A1 (en) | 2018-10-22 | 2020-04-30 | University Of Rochester | Genome editing by directed non-homologous dna insertion using a retroviral integrase-cas9 fusion protein |
WO2020092455A2 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Car t cell transcriptional atlas |
WO2020102676A1 (en) | 2018-11-16 | 2020-05-22 | Celgene Corporation | Improved t cell manufacturing process |
WO2020102555A1 (en) | 2018-11-16 | 2020-05-22 | Memorial Sloan Kettering Cancer Center | Antibodies to mucin-16 and methods of use thereof |
EP3660042A1 (en) | 2014-07-31 | 2020-06-03 | Novartis AG | Subset-optimized chimeric antigen receptor-containing t-cells |
US10689873B2 (en) | 2016-03-10 | 2020-06-23 | Lonza Ltd | Customizable facility |
WO2020140007A1 (en) | 2018-12-28 | 2020-07-02 | University Of Rochester | Gene therapy for best1 dominant mutations |
WO2020150287A1 (en) | 2019-01-14 | 2020-07-23 | University Of Rochester | Targeted nuclear rna cleavage and polyadenylation with crispr-cas |
WO2020152451A1 (en) | 2019-01-22 | 2020-07-30 | Immetacyte Limited | Receptors providing targeted costimulation for adoptive cell therapy |
US10730954B2 (en) | 2017-05-12 | 2020-08-04 | Harpoon Therapeutics, Inc. | MSLN targeting trispecific proteins and methods of use |
US10738099B2 (en) | 2015-09-22 | 2020-08-11 | The Trustees Of The University Of Pennsylvania | Method of redirecting T cells to treat HIV infection |
WO2020161186A1 (en) | 2019-02-08 | 2020-08-13 | Biontech Cell & Gene Therapies Gmbh | Chimeric antigen receptor-modified cells for the treatment of cldn6-expressing cancers |
EP3699284A1 (en) | 2012-07-05 | 2020-08-26 | The Trustees of the University of Pennsylvania | U1 snrnp regulates gene expression and modulates oncogenicity |
WO2020172553A1 (en) | 2019-02-22 | 2020-08-27 | Novartis Ag | Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors |
WO2020185121A2 (en) | 2019-03-13 | 2020-09-17 | Общество С Ограниченной Ответственностью "Анабион" | Isolated alternative intracellular signalling domain of a chimeric antigen receptor and chimeric antigen receptor comprising said signalling domain |
EP3712171A1 (en) | 2014-08-19 | 2020-09-23 | Novartis AG | Treatment of cancer using a cd123 chimeric antigen receptor |
WO2020188103A1 (en) | 2019-03-20 | 2020-09-24 | Centre National De La Recherche Scientifique | Amphiphysin / bin1 for the treatment of autosomal dominant centronuclear myopathy |
EP3722316A1 (en) | 2014-07-21 | 2020-10-14 | Novartis AG | Treatment of cancer using a cd33 chimeric antigen receptor |
WO2020210678A1 (en) | 2019-04-12 | 2020-10-15 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
US10808031B2 (en) | 2015-01-21 | 2020-10-20 | Cancer Research Technology Limited | Inhibitors of the interaction between CLEC14A and multimerin-2 for inhibition of angiogenesis |
US10815311B2 (en) | 2018-09-25 | 2020-10-27 | Harpoon Therapeutics, Inc. | DLL3 binding proteins and methods of use |
WO2020219742A1 (en) | 2019-04-24 | 2020-10-29 | Novartis Ag | Compositions and methods for selective protein degradation |
WO2020224606A1 (en) | 2019-05-07 | 2020-11-12 | 亘喜生物科技(上海)有限公司 | Engineered immune cell targeting bcma and use thereof |
US10844134B2 (en) | 2016-11-23 | 2020-11-24 | Harpoon Therapeutics, Inc. | PSMA targeting trispecific proteins and methods of use |
US10849973B2 (en) | 2016-11-23 | 2020-12-01 | Harpoon Therapeutics, Inc. | Prostate specific membrane antigen binding protein |
WO2021003442A1 (en) | 2019-07-02 | 2021-01-07 | M6P Therapeutics | Vector compositions and methods of using same for treatment of lysosomal storage disorders |
WO2021016453A1 (en) | 2019-07-23 | 2021-01-28 | University Of Rochester | Targeted rna cleavage with crispr-cas |
WO2021016608A1 (en) | 2019-07-25 | 2021-01-28 | Precision Biosciences, Inc. | Compositions and methods for sequential stacking of nucleic acid sequences into a genomic locus |
WO2021018311A1 (en) | 2019-08-01 | 2021-02-04 | 上海赛比曼生物科技有限公司 | Universal car-t cell and preparation and use thereof |
WO2021030182A1 (en) | 2019-08-09 | 2021-02-18 | A2 Biotherapeutics, Inc. | Bifunctional single variable domain t cell receptors and uses thereof |
US10927180B2 (en) | 2017-10-13 | 2021-02-23 | Harpoon Therapeutics, Inc. | B cell maturation antigen binding proteins |
WO2021035054A1 (en) | 2019-08-20 | 2021-02-25 | Precision Biosciences, Inc. | Lymphodepletion dosing regimens for cellular immunotherapies |
WO2021035170A1 (en) | 2019-08-21 | 2021-02-25 | Precision Biosciences, Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
WO2021032779A1 (en) | 2019-08-19 | 2021-02-25 | Universität Basel | Cell therapy methods |
US10934337B2 (en) | 2019-03-15 | 2021-03-02 | Cartesian Therapeutics, Inc. | Anti-BCMA chimeric antigen receptors |
US10934336B2 (en) | 2017-04-13 | 2021-03-02 | The Trustees Of The University Of Pennsylvania | Use of gene editing to generate universal TCR re-directed T cells for adoptive immunotherapy |
US10954311B2 (en) | 2015-05-21 | 2021-03-23 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
EP3808766A1 (en) | 2019-10-15 | 2021-04-21 | Sangamo Therapeutics France | Chimeric antigen receptor specific for interleukin-23 receptor |
EP3811970A1 (en) | 2014-03-15 | 2021-04-28 | Novartis AG | Regulatable chimeric antigen receptor |
WO2021096868A1 (en) | 2019-11-12 | 2021-05-20 | A2 Biotherapeutics, Inc. | Engineered t cell receptors and uses thereof |
WO2021094461A1 (en) | 2019-11-14 | 2021-05-20 | Lonza Ltd | Methods of cell selection |
WO2021098882A1 (en) | 2019-11-21 | 2021-05-27 | 博生吉医药科技(苏州)有限公司 | Cd7-car-t cell and preparation and application thereof |
WO2021108613A1 (en) | 2019-11-26 | 2021-06-03 | Novartis Ag | Cd19 and cd22 chimeric antigen receptors and uses thereof |
WO2021108661A2 (en) | 2019-11-26 | 2021-06-03 | Novartis Ag | Chimeric antigen receptors and uses thereof |
WO2021119489A1 (en) | 2019-12-11 | 2021-06-17 | A2 Biotherapeutics, Inc. | Lilrb1-based chimeric antigen receptor |
WO2021158964A1 (en) | 2020-02-07 | 2021-08-12 | University Of Rochester | Ribozyme-mediated rna assembly and expression |
WO2021158982A2 (en) | 2020-02-07 | 2021-08-12 | University Of Rochester | Targeted translation of rna with crispr-cas13 to enhance protein synthesis |
US11090336B2 (en) | 2019-03-27 | 2021-08-17 | The Trustees Of The University Of Pennsylvania | Tn-MUC1 chimeric antigen receptor (CAR) T cell therapy |
WO2021163618A1 (en) | 2020-02-14 | 2021-08-19 | Novartis Ag | Method of predicting response to chimeric antigen receptor therapy |
WO2021170071A1 (en) | 2020-02-28 | 2021-09-02 | Shanghai Henlius Biotech, Inc. | Anti-cd137 constructs, multispecific antibody and uses thereof |
WO2021170067A1 (en) | 2020-02-28 | 2021-09-02 | 上海复宏汉霖生物技术股份有限公司 | Anti-cd137 construct and use thereof |
WO2021173995A2 (en) | 2020-02-27 | 2021-09-02 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
WO2021173985A2 (en) | 2020-02-27 | 2021-09-02 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
WO2021173674A1 (en) | 2020-02-26 | 2021-09-02 | A2 Biotherapeutics, Inc. | Polypeptides targeting mage-a3 peptide-mhc complexes and methods of use thereof |
WO2021186246A1 (en) | 2020-03-19 | 2021-09-23 | Trizell Ltd. | Temperature-responsive virus storage system |
WO2021186056A1 (en) | 2020-03-20 | 2021-09-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Chimeric antigen receptor specific for human cd45rc and uses thereof |
US11130783B2 (en) | 2018-11-13 | 2021-09-28 | Regents Of The University Of Minnesota | CD40 targeted peptides and uses thereof |
WO2021195519A1 (en) | 2020-03-27 | 2021-09-30 | University Of Rochester | Targeted destruction of viral rna by crispr-cas13 |
WO2021195525A1 (en) | 2020-03-27 | 2021-09-30 | University Of Rochester | Crispr-cas13 crrna arrays |
US11136403B2 (en) | 2017-10-13 | 2021-10-05 | Harpoon Therapeutics, Inc. | Trispecific proteins and methods of use |
WO2021208750A1 (en) | 2020-04-16 | 2021-10-21 | 上海赛比曼生物科技有限公司 | Cd22-targeted chimeric antigen receptor, preparation method therefor and application thereof |
WO2021222576A1 (en) | 2020-05-01 | 2021-11-04 | A2 Biotherapeutics, Inc. | Pag1 fusion proteins and methods of making and using same |
US11180563B2 (en) | 2020-02-21 | 2021-11-23 | Harpoon Therapeutics, Inc. | FLT3 binding proteins and methods of use |
WO2021238886A1 (en) | 2020-05-27 | 2021-12-02 | Staidson (Beijing) Biopharmaceuticals Co., Ltd. | Antibodies specifically recognizing nerve growth factor and uses thereof |
WO2021252635A1 (en) | 2020-06-11 | 2021-12-16 | A2 Biotherapeutics, Inc. | Compositions and methods for treating cancers |
WO2021252920A1 (en) | 2020-06-11 | 2021-12-16 | Novartis Ag | Zbtb32 inhibitors and uses thereof |
US11219675B2 (en) | 2015-03-13 | 2022-01-11 | Syz Cell Therapy Co. | Methods of cancer treatment using activated T cells |
US11219676B2 (en) | 2018-04-13 | 2022-01-11 | Syz Cell Therapy Co. | Methods of cancer treatment using tumor antigen-specific T cells |
WO2022011651A1 (en) | 2020-07-16 | 2022-01-20 | 上海交通大学 | Immunotherapy method of targeted chemokine and cytokine delivery by mesenchymal stem cell |
WO2022016112A1 (en) | 2020-07-17 | 2022-01-20 | Instil Bio (Uk) Limited | Receptors providing targeted costimulation for adoptive cell therapy |
WO2022016114A1 (en) | 2020-07-17 | 2022-01-20 | Instill Bio (Uk) Limited | Chimeric molecules providing targeted costimulation for adoptive cell therapy |
WO2022015916A1 (en) | 2020-07-15 | 2022-01-20 | University Of Rochester | Targeted rna cleavage with dcasl3-rnase fusion proteins |
US11236520B2 (en) | 2016-03-10 | 2022-02-01 | Lonza Ltd | Customizable facility |
US11248208B2 (en) | 2018-03-30 | 2022-02-15 | Syz Cell Therapy Co. | Multiple antigen specific cell therapy methods |
WO2022036068A1 (en) | 2020-08-13 | 2022-02-17 | A2 Biotherapeutics, Inc. | Gene fusions for control of genetically modified cells |
US11274157B2 (en) | 2017-01-12 | 2022-03-15 | Eureka Therapeutics, Inc. | Constructs targeting histone H3 peptide/MHC complexes and uses thereof |
WO2022079308A1 (en) | 2020-10-16 | 2022-04-21 | Institut Pasteur | Chimeric constructs useful in vaccination and cancer therapy |
WO2022104061A1 (en) | 2020-11-13 | 2022-05-19 | Novartis Ag | Combination therapies with chimeric antigen receptor (car)-expressing cells |
WO2022105893A1 (en) | 2020-11-23 | 2022-05-27 | 博生吉医药科技(苏州)有限公司 | Preparation method and application of cd7-car-t cells |
WO2022123316A1 (en) | 2020-12-09 | 2022-06-16 | Takeda Pharmaceutical Company Limited | Compositions of guanylyl cyclase c (gcc) antigen binding agents and methods of use thereof |
WO2022123307A1 (en) | 2020-12-09 | 2022-06-16 | Takeda Pharmaceutical Company Limited | Compositions of guanylyl cyclase c (gcc) antigen binding agents and methods of use thereof |
WO2022147463A2 (en) | 2020-12-31 | 2022-07-07 | Alamar Biosciences, Inc. | Binder molecules with high affinity and/ or specificity and methods of making and use thereof |
US11390659B2 (en) | 2018-04-13 | 2022-07-19 | Syz Cell Therapy Co. | Methods of obtaining tumor-specific T cell receptors |
WO2022155421A1 (en) | 2021-01-15 | 2022-07-21 | University Of Rochester | Staphylococcus aureus antigen-based nucleic acid vaccines |
WO2022151960A1 (en) | 2021-01-13 | 2022-07-21 | 博生吉医药科技(苏州)有限公司 | B7-h3 chimeric antigen receptor-modified t cell and use thereof |
US11396552B2 (en) | 2018-02-12 | 2022-07-26 | Diabetes-Free Inc. | Antagonistic anti-human CD40 monoclonal antibodies |
EP4036109A2 (en) | 2014-12-29 | 2022-08-03 | Novartis AG | Methods of making chimeric antigen receptor-expressing cells |
WO2022162192A2 (en) | 2021-01-29 | 2022-08-04 | Thelper As | Therapeutic and diagnostic agents and uses thereof |
WO2022165111A1 (en) | 2021-01-28 | 2022-08-04 | Precision Biosciences, Inc. | Modulation of tgf beta signaling in genetically-modified eukaryotic cells |
WO2022166665A1 (en) | 2021-02-08 | 2022-08-11 | 浙江大学 | Chimeric antigen receptor with endogenous protein molecule replacing single domain antibody |
US11433100B2 (en) | 2020-08-20 | 2022-09-06 | A2 Biotherapeutics, Inc. | Compositions and methods for treating ceacam positive cancers |
US11440958B2 (en) | 2016-11-22 | 2022-09-13 | National University Of Singapore | Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies |
US11441146B2 (en) | 2016-01-11 | 2022-09-13 | Christiana Care Health Services, Inc. | Compositions and methods for improving homogeneity of DNA generated using a CRISPR/Cas9 cleavage system |
US11447564B2 (en) | 2017-04-26 | 2022-09-20 | Eureka Therapeutics, Inc. | Constructs specifically recognizing glypican 3 and uses thereof |
US11453716B2 (en) | 2016-05-20 | 2022-09-27 | Harpoon Therapeutics, Inc. | Single domain serum albumin binding protein |
WO2022226296A2 (en) | 2021-04-23 | 2022-10-27 | University Of Rochester | Genome editing by directed non-homologous dna insertion using a retroviral integrase-cas fusion protein and methods of treatment |
US11485782B2 (en) | 2018-03-14 | 2022-11-01 | Beijing Xuanyi Pharmasciences Co., Ltd. | Anti-claudin 18.2 antibodies |
WO2022254337A1 (en) | 2021-06-01 | 2022-12-08 | Novartis Ag | Cd19 and cd22 chimeric antigen receptors and uses thereof |
WO2022262764A1 (en) | 2021-06-16 | 2022-12-22 | 四川大学华西医院 | Preparation and application of lox1-based chimeric antigen receptor immune cell |
WO2022266660A1 (en) | 2021-06-17 | 2022-12-22 | Amberstone Biosciences, Inc. | Anti-cd3 constructs and uses thereof |
WO2022262765A1 (en) | 2021-06-16 | 2022-12-22 | 四川大学华西医院 | Preparation and application of chimeric antigen receptor immune cell constructed on basis of granzyme b |
US11535668B2 (en) | 2017-02-28 | 2022-12-27 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
WO2022271955A1 (en) | 2021-06-23 | 2022-12-29 | Musc Foundation For Research Development | Novel targeted shrna nanoparticles for cancer therapy |
WO2023278641A1 (en) | 2021-06-29 | 2023-01-05 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
WO2023283611A1 (en) | 2021-07-08 | 2023-01-12 | Staidson Biopharma Inc. | Antibodies specifically recognizing tnfr2 and uses thereof |
WO2023284714A1 (en) | 2021-07-14 | 2023-01-19 | 舒泰神(北京)生物制药股份有限公司 | Antibody that specifically recognizes cd40 and application thereof |
US11602544B2 (en) | 2020-08-20 | 2023-03-14 | A2 Biotherapeutics, Inc. | Compositions and methods for treating EGFR positive cancers |
US11602543B2 (en) | 2020-08-20 | 2023-03-14 | A2 Biotherapeutics, Inc. | Compositions and methods for treating mesothelin positive cancers |
US11607453B2 (en) | 2017-05-12 | 2023-03-21 | Harpoon Therapeutics, Inc. | Mesothelin binding proteins |
WO2023056329A1 (en) | 2021-09-30 | 2023-04-06 | Akouos, Inc. | Compositions and methods for treating kcnq4-associated hearing loss |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
WO2023069979A1 (en) | 2021-10-20 | 2023-04-27 | University Of Rochester | Isolated glial progenitor cells for use in the competition treatment of age-related white matter loss |
WO2023081633A1 (en) | 2021-11-02 | 2023-05-11 | University Of Rochester | Tcf7l2 mediated remyelination in the brain |
WO2023086939A1 (en) | 2021-11-12 | 2023-05-19 | Amicus Therapeutics, Inc. | Compositions and methods for treating mucopolysaccharidosis iiia |
WO2023089556A1 (en) | 2021-11-22 | 2023-05-25 | Pfizer Inc. | Reducing risk of antigen mimicry in immunogenic medicaments |
WO2023105005A1 (en) | 2021-12-09 | 2023-06-15 | BioNTech SE | Chimeric antigen receptor-modified cells for the treatment of cldn6 expressing cancer |
US11679132B2 (en) | 2015-02-06 | 2023-06-20 | National University Of Singapore | Methods for enhancing efficacy of therapeutic immune cells |
US11697677B2 (en) | 2021-07-16 | 2023-07-11 | Instil Bio (Uk) Limited | Chimeric molecules providing targeted costimulation for adoptive cell therapy |
WO2023144779A1 (en) | 2022-01-28 | 2023-08-03 | Pfizer Inc. | Coronavirus antigen variants |
WO2023144392A1 (en) | 2022-01-28 | 2023-08-03 | Thelper As | Therapeutic and diagnostic agents and uses thereof |
US11730764B2 (en) | 2021-02-16 | 2023-08-22 | A2 Biotherapeutics, Inc. | Compositions and methods for treating HER2 positive cancers |
WO2023177954A1 (en) | 2022-03-18 | 2023-09-21 | University Of Rochester | Combination therapy for treatment of cancer, methods and systems of delivery thereof |
WO2023215860A1 (en) | 2022-05-05 | 2023-11-09 | University Of Rochester | Modified bacteria and methods of use for bioglass microlenses |
US11814432B2 (en) | 2017-09-20 | 2023-11-14 | The University Of British Columbia | Anti-HLA-A2 antibodies, related chimeric antigen receptors, and uses thereof |
WO2024020407A1 (en) | 2022-07-19 | 2024-01-25 | Staidson Biopharma Inc. | Antibodies specifically recognizing b- and t-lymphocyte attenuator (btla) and uses thereof |
WO2024046572A1 (en) | 2022-09-01 | 2024-03-07 | BioNTech SE | Chimeric antigen receptor-modified cells for the treatment of cldn6 expressing cancer |
WO2024056809A1 (en) | 2022-09-15 | 2024-03-21 | Novartis Ag | Treatment of autoimmune disorders using chimeric antigen receptor therapy |
US11945876B2 (en) | 2021-06-16 | 2024-04-02 | Instil Bio (Uk) Limited | Receptors providing targeted costimulation for adoptive cell therapy |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8202979B2 (en) | 2002-02-20 | 2012-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992017054A1 (en) * | 1991-03-26 | 1992-10-15 | Mogen International N.V. | Method for the isolation and/or testing of genes and promoters involved in plant-nematode interactions using plants of the genus arabidopsis |
WO1993010251A1 (en) * | 1991-11-20 | 1993-05-27 | Mogen International N.V. | A method for obtaining plants with reduced susceptibility to plant-parasitic nematodes |
WO1999032619A1 (en) * | 1997-12-23 | 1999-07-01 | The Carnegie Institution Of Washington | Genetic inhibition by double-stranded rna |
WO2000001846A2 (en) * | 1998-07-03 | 2000-01-13 | Devgen N.V. | Characterisation of gene function using double stranded rna inhibition |
WO2001037654A2 (en) * | 1999-11-24 | 2001-05-31 | Dna Plant Technology Corporation | METHOD OF EXPRESSING dsRNA IN PLANTS TO INHIBIT INSECT PESTS |
-
2001
- 2001-06-12 WO PCT/US2001/018911 patent/WO2001096584A2/en active Application Filing
- 2001-06-12 AU AU2001275474A patent/AU2001275474A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992017054A1 (en) * | 1991-03-26 | 1992-10-15 | Mogen International N.V. | Method for the isolation and/or testing of genes and promoters involved in plant-nematode interactions using plants of the genus arabidopsis |
WO1993010251A1 (en) * | 1991-11-20 | 1993-05-27 | Mogen International N.V. | A method for obtaining plants with reduced susceptibility to plant-parasitic nematodes |
WO1999032619A1 (en) * | 1997-12-23 | 1999-07-01 | The Carnegie Institution Of Washington | Genetic inhibition by double-stranded rna |
WO2000001846A2 (en) * | 1998-07-03 | 2000-01-13 | Devgen N.V. | Characterisation of gene function using double stranded rna inhibition |
WO2001037654A2 (en) * | 1999-11-24 | 2001-05-31 | Dna Plant Technology Corporation | METHOD OF EXPRESSING dsRNA IN PLANTS TO INHIBIT INSECT PESTS |
Non-Patent Citations (3)
Title |
---|
BASS BRENDA L: "Double-stranded RNA as a template for gene silencing." CELL, vol. 101, no. 3, 28 April 2000 (2000-04-28), pages 235-238, XP002194756 ISSN: 0092-8674 cited in the application * |
NIEBEL ET AL: "induction of cdc2a and cyc1at expression in Arabidopsis thaliana during early phases of nematode-induced feeding cell formation" PLANT JOURNAL, BLACKWELL SCIENTIFIC PUBLICATIONS, OXFORD, GB, vol. 10, no. 6, 1996, pages 1037-1043, XP002086054 ISSN: 0960-7412 * |
WANG YONGZENG ET AL: "Identification of a novel plant virus promoter using a potyvirus infectious clone." VIRUS GENES, vol. 20, no. 1, February 2000 (2000-02), pages 11-17, XP008002062 ISSN: 0920-8569 * |
Cited By (532)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8017765B2 (en) | 2000-08-30 | 2011-09-13 | Merck Sharp & Dohme Corp. | RNA interference mediated treatment of alzheimer's disease using short interfering nucleic acid (siNA) |
US7662951B2 (en) | 2000-08-30 | 2010-02-16 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA) |
US7022828B2 (en) | 2001-04-05 | 2006-04-04 | Sirna Theraputics, Inc. | siRNA treatment of diseases or conditions related to levels of IKK-gamma |
US7491805B2 (en) | 2001-05-18 | 2009-02-17 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
US8017761B2 (en) | 2001-05-18 | 2011-09-13 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of Stearoyl-CoA desaturase (SCD) gene expression using short interfering nucelic acid (siNA) |
US7659389B2 (en) | 2001-05-18 | 2010-02-09 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of MYC and/or MYB gene expression using short interfering nucleic acid (siNA) |
US9994853B2 (en) | 2001-05-18 | 2018-06-12 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
US7833992B2 (en) | 2001-05-18 | 2010-11-16 | Merck Sharpe & Dohme | Conjugates and compositions for cellular delivery |
US7964578B2 (en) | 2001-05-18 | 2011-06-21 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
US8008472B2 (en) | 2001-05-29 | 2011-08-30 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA) |
US7422896B1 (en) | 2001-12-27 | 2008-09-09 | Allele Biotechnology & Pharmaceuticals, Inc. | Compositions for DNA mediated gene silencing |
US7294504B1 (en) | 2001-12-27 | 2007-11-13 | Allele Biotechnology & Pharmaceuticals, Inc. | Methods and compositions for DNA mediated gene silencing |
US7625750B2 (en) | 2001-12-27 | 2009-12-01 | Allele Biotechnology & Pharmaceuticals, Inc. | Compositions for DNA mediated gene silencing |
EP2221377B1 (en) † | 2002-02-01 | 2011-10-19 | Life Technologies Corporation | Oligonucleotide compositions with enhanced efficiency |
US10626398B2 (en) | 2002-02-01 | 2020-04-21 | Life Technologies Corporation | Oligonucleotide compositions with enhanced efficiency |
EP1572902A4 (en) * | 2002-02-01 | 2007-04-11 | Ambion Inc | HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES |
EP1572902A2 (en) * | 2002-02-01 | 2005-09-14 | Ambion, Inc. | HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES |
US10196640B1 (en) | 2002-02-01 | 2019-02-05 | Life Technologies Corporation | Oligonucleotide compositions with enhanced efficiency |
US10106793B2 (en) | 2002-02-01 | 2018-10-23 | Life Technologies Corporation | Double-stranded oligonucleotides |
US10036025B2 (en) | 2002-02-01 | 2018-07-31 | Life Technologies Corporation | Oligonucleotide compositions with enhanced efficiency |
US9796978B1 (en) | 2002-02-01 | 2017-10-24 | Life Technologies Corporation | Oligonucleotide compositions with enhanced efficiency |
US9777275B2 (en) | 2002-02-01 | 2017-10-03 | Life Technologies Corporation | Oligonucleotide compositions with enhanced efficiency |
EP2221377B2 (en) † | 2002-02-01 | 2017-05-17 | Life Technologies Corporation | Oligonucleotide compositions with enhanced efficiency |
US7700760B2 (en) | 2002-02-20 | 2010-04-20 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA) |
US8076472B2 (en) | 2002-02-20 | 2011-12-13 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of muscarinic colinergic receptor gene expression using short interfering nucleic acid (siNA) |
US10662428B2 (en) | 2002-02-20 | 2020-05-26 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US9657294B2 (en) | 2002-02-20 | 2017-05-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US9732344B2 (en) | 2002-02-20 | 2017-08-15 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US9738899B2 (en) | 2002-02-20 | 2017-08-22 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US10351852B2 (en) | 2002-02-20 | 2019-07-16 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US9771588B2 (en) | 2002-02-20 | 2017-09-26 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
WO2003070886A2 (en) * | 2002-02-20 | 2003-08-28 | Sirna Therapeutics, Inc. | Inhibition of protein tyrosine phosphatase type iva expression byshort interfering nucleic acid |
US8258288B2 (en) | 2002-02-20 | 2012-09-04 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of respiratory syncytial virus (RSV) expression using short interfering nucleic acid (siNA) |
US8153778B2 (en) | 2002-02-20 | 2012-04-10 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA) |
US7659390B2 (en) | 2002-02-20 | 2010-02-09 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of muscarinic colinergic receptor gene expression using short interfering nucleic acid (siNA) |
US7662952B2 (en) | 2002-02-20 | 2010-02-16 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acid (siNA) |
WO2003070886A3 (en) * | 2002-02-20 | 2004-04-01 | Sirna Therapeutics Inc | Inhibition of protein tyrosine phosphatase type iva expression byshort interfering nucleic acid |
US7667029B2 (en) | 2002-02-20 | 2010-02-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of checkpoint kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA) |
US7667030B2 (en) | 2002-02-20 | 2010-02-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA) |
US7678897B2 (en) | 2002-02-20 | 2010-03-16 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA) |
US10889815B2 (en) | 2002-02-20 | 2021-01-12 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US7691999B2 (en) | 2002-02-20 | 2010-04-06 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of NOGO and NOGO receptor gene expression using short interfering nucleic acid (siNA) |
WO2003070918A3 (en) * | 2002-02-20 | 2004-07-08 | Ribozyme Pharm Inc | Rna interference by modified short interfering nucleic acid |
US8067575B2 (en) | 2002-02-20 | 2011-11-29 | Merck, Sharp & Dohme Corp. | RNA interference mediated inhibition of cyclin D1 gene expression using short interfering nucleic acid (siNA) |
US8013146B2 (en) | 2002-02-20 | 2011-09-06 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA) |
US8013143B2 (en) | 2002-02-20 | 2011-09-06 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of CXCR4 gene expression using short interfering nucleic acid (siNA) |
US8008473B2 (en) | 2002-02-20 | 2011-08-30 | Mcswiggen James | RNA interference mediated inhibition of TNF and TNF receptor gene expression using short interfering nucleic acid (siNA) |
US7795422B2 (en) | 2002-02-20 | 2010-09-14 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA) |
US7985853B2 (en) | 2002-02-20 | 2011-07-26 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of platelet derived growth factor (PDGF) and platelet derived growth factor receptor (PDGFR) gene expression using short interfering nucleic acid (siNA) |
US7977472B2 (en) | 2002-02-20 | 2011-07-12 | Leonid Beigelman | RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA) |
US9957517B2 (en) | 2002-02-20 | 2018-05-01 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US7855284B2 (en) | 2002-02-20 | 2010-12-21 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of checkpoint kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA) |
US7858771B2 (en) | 2002-02-20 | 2010-12-28 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of muscarinic colinergic receptor gene expression using short interfering nucleic acid (siNA) |
GB2397818B (en) * | 2002-02-20 | 2005-03-09 | Sirna Therapeutics Inc | Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
GB2397818A (en) * | 2002-02-20 | 2004-08-04 | Sirna Therapeutics Inc | Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
US7956178B2 (en) | 2002-02-20 | 2011-06-07 | Mcswiggen James | RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acid (siNA) |
US10000754B2 (en) | 2002-02-20 | 2018-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US7893248B2 (en) | 2002-02-20 | 2011-02-22 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA) |
US7897752B2 (en) | 2002-02-20 | 2011-03-01 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of telomerase gene expression using short interfering nucleic acid (siNA) |
US7897755B2 (en) | 2002-02-20 | 2011-03-01 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA) |
US7897757B2 (en) | 2002-02-20 | 2011-03-01 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA) |
US7897756B2 (en) | 2002-02-20 | 2011-03-01 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of NOGO and NOGO receptor gene expression using short interfering nucleic acid (siNA) |
US7897753B2 (en) | 2002-02-20 | 2011-03-01 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of XIAP gene expression using short interfering nucleic acid (siNA) |
US7910724B2 (en) | 2002-02-20 | 2011-03-22 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of Fos gene expression using short interfering nucleic acid (siNA) |
US7910725B2 (en) | 2002-02-20 | 2011-03-22 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA) |
US7915400B2 (en) | 2002-02-20 | 2011-03-29 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (siNA) |
US7943757B2 (en) | 2002-02-20 | 2011-05-17 | Mcswiggen James | RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA) |
US7923549B2 (en) | 2002-02-20 | 2011-04-12 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA) |
US7928220B2 (en) | 2002-02-20 | 2011-04-19 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of stromal cell-derived factor-1 (SDF-1) gene expression using short interfering nucleic acid (siNA) |
US7928219B2 (en) | 2002-02-20 | 2011-04-19 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (SINA) |
US7935812B2 (en) | 2002-02-20 | 2011-05-03 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA) |
WO2003093475A1 (en) * | 2002-04-30 | 2003-11-13 | Genesis Research And Development Corporation Limited | Compositions and methods for the modification of gene expression_using the superubiquitin promoter from pinus radiata |
US9267145B2 (en) | 2002-05-03 | 2016-02-23 | Duke University | Method of regulating gene expression |
US9856476B2 (en) | 2002-05-03 | 2018-01-02 | Duke University | Method of regulating gene expression |
US9850485B2 (en) | 2002-05-03 | 2017-12-26 | Duke University | Method of regulating gene expression |
US10233451B2 (en) | 2002-05-03 | 2019-03-19 | Duke University | Method of regulating gene expression |
US7803984B2 (en) * | 2002-07-10 | 2010-09-28 | Kansas State University Research Foundation | Compositions and methods for controlling plant parasitic nematodes |
US8999654B2 (en) | 2002-09-09 | 2015-04-07 | Omeros Corporation | Method of identifying a compound for the treatment or prevention of obesity |
US10292374B2 (en) | 2002-09-09 | 2019-05-21 | Omeros Corporation | G protein coupled receptor 85 and SREB3 knockout mice and uses thereof |
US8158420B2 (en) | 2003-04-04 | 2012-04-17 | The Trustees Of Columbia University In The City Of New York | Methods for inhibiting the differentation of proliferative telencephalic cells in vitro by addition of ATF5 |
US7888326B2 (en) | 2003-04-04 | 2011-02-15 | The Trustees Of Columbia University In The City Of New York | Methods for promoting apoptosis and treating tumor cells inhibiting the expression or function of the transcription factor ATF5 |
US9132167B2 (en) | 2003-05-19 | 2015-09-15 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for treating and preventing heart tissue degeneration and uses thereof |
US7645734B2 (en) | 2003-05-19 | 2010-01-12 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for treating and preventing heart tissue degeneration and uses thereof |
US8217157B2 (en) | 2003-05-19 | 2012-07-10 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for treating and preventing heart tissue degeneration, and uses thereof |
WO2005071091A1 (en) * | 2003-12-23 | 2005-08-04 | Bayer Cropscience Sa | Method for modifying gene expression of a phytopathogenic fungus |
US7741531B2 (en) | 2003-12-23 | 2010-06-22 | Bayer S.A.S. | Method for modifying gene expression of a phytopathogenic fungus |
US7858769B2 (en) | 2004-02-10 | 2010-12-28 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using multifunctional short interfering nucleic acid (multifunctional siNA) |
US7622301B2 (en) | 2004-02-24 | 2009-11-24 | Basf Plant Science Gmbh | Compositions and methods using RNA interference for control of nematodes |
EP2163560A2 (en) * | 2004-02-24 | 2010-03-17 | BASF Plant Science GmbH | Compositions and methods using RNA interference for control of nematodes in plants |
WO2005082932A2 (en) * | 2004-02-24 | 2005-09-09 | Basf Plant Science Gmbh | Compositions and methods using rna interference for control of nematodes in plants |
EP2163560A3 (en) * | 2004-02-24 | 2010-06-02 | BASF Plant Science GmbH | Compositions and methods using RNA interference for control of nematodes in plants |
WO2005082932A3 (en) * | 2004-02-24 | 2005-11-10 | Basf Plant Science Gmbh | Compositions and methods using rna interference for control of nematodes in plants |
US10508277B2 (en) | 2004-05-24 | 2019-12-17 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
US7868158B2 (en) | 2004-07-19 | 2011-01-11 | Baylor College Of Medicine | Modulation of cytokine signaling regulators and applications for immunotherapy |
WO2006020821A2 (en) | 2004-08-13 | 2006-02-23 | Basf Plant Science Gmbh | Compositions and methods using rna interference for control of nematodes |
WO2006020821A3 (en) * | 2004-08-13 | 2006-05-18 | Basf Plant Science Gmbh | Compositions and methods using rna interference for control of nematodes |
US7659444B2 (en) | 2004-08-13 | 2010-02-09 | Basf Plant Science Gmbh | Compositions and methods using RNA interference for control of nematodes |
US8865968B2 (en) | 2004-10-04 | 2014-10-21 | Devgen Nv | Method for down-regulating gene expression in fungi |
US7915479B2 (en) | 2004-10-13 | 2011-03-29 | University Of Georgia Research Foundation, Inc. | Nematode resistant transgenic plants |
US7576261B2 (en) | 2004-10-13 | 2009-08-18 | University Of Georgia Research Foundation, Inc. | Nematode resistant transgenic plants |
WO2006047495A2 (en) | 2004-10-21 | 2006-05-04 | Venganza Inc | Methods and materials for conferring resistance to pests and pathogens of plants |
US9121034B2 (en) | 2004-10-21 | 2015-09-01 | Venganza Inc | Methods and materials for conferring resistance to pests and pathogens of corn |
US8461416B2 (en) | 2004-10-21 | 2013-06-11 | Venganza, Inc. | Methods and materials for conferring resistance to pests and pathogens of plants |
WO2006047495A3 (en) * | 2004-10-21 | 2006-08-24 | Charles L Niblett | Methods and materials for conferring resistance to pests and pathogens of plants |
EP2336333A1 (en) * | 2004-10-21 | 2011-06-22 | Venganza Inc. | Methods and materials for conferring resistance to pests and pathogens of plants |
JP2008517604A (en) * | 2004-10-21 | 2008-05-29 | ヴェンガンザ インコーポレイテッド | Methods and materials for conferring resistance to plant pests and pathogens |
US8581039B2 (en) | 2004-10-21 | 2013-11-12 | Venganza, Inc. | Methods and materials for conferring resistance to pests and pathogens of plants |
US8148604B2 (en) | 2004-10-21 | 2012-04-03 | Venganza Inc. | Methods and materials for conferring resistance to pests and pathogens of plants |
US9944713B2 (en) | 2004-11-24 | 2018-04-17 | Medicinal Bioconvergence Research Center | Antibody specific to the AIMP2-DX2 |
EP2500429A2 (en) | 2005-05-31 | 2012-09-19 | Devgen N.V. | RNAi for the control of insects and arachnids |
US8759306B2 (en) | 2005-05-31 | 2014-06-24 | Devgen N.V. | RNAi for the control of insects and arachnids |
US9290764B2 (en) | 2005-05-31 | 2016-03-22 | Devgen Nv | RNAi for the control of insects and arachnids |
US7868159B2 (en) | 2005-06-23 | 2011-01-11 | Baylor College Of Medicine | Modulation of negative immune regulators and applications for immunotherapy |
US8221740B2 (en) | 2005-09-26 | 2012-07-17 | The Trustees Of Columbia University In The City Of New York | Side population cells in cardiac repair |
JP2009523017A (en) * | 2006-01-12 | 2009-06-18 | デブジェン エヌブイ | Genetically modified plant system method for plant pests using RNAi |
JP2009523018A (en) * | 2006-01-12 | 2009-06-18 | デブジェン エヌブイ | Method for controlling pests using RNAi |
WO2007104570A2 (en) * | 2006-03-16 | 2007-09-20 | Devgen N.V. | Nematode control |
WO2007104570A3 (en) * | 2006-03-16 | 2008-04-17 | Devgen Nv | Nematode control |
WO2007117657A2 (en) | 2006-04-07 | 2007-10-18 | The Research Foundation Of State University Of New York | Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency |
US9044461B2 (en) | 2006-04-07 | 2015-06-02 | The Research Foundation Of State University Of New York | Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency |
US8524454B2 (en) | 2006-04-07 | 2013-09-03 | The Research Foundation Of State University Of New York | Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency |
WO2008095886A1 (en) | 2007-02-06 | 2008-08-14 | Basf Plant Science Gmbh | Compositions and methods using rna interference for control of nematodes |
WO2008095910A1 (en) | 2007-02-08 | 2008-08-14 | Basf Plant Science Gmbh | Compositions and methods using rna interference of opr3-like gene for control of nematodes |
WO2008095970A1 (en) | 2007-02-09 | 2008-08-14 | Basf Plant Science Gmbh | Compositions and methods using rna interference of cdpk-like for control of nematodes |
WO2008118324A2 (en) | 2007-03-26 | 2008-10-02 | Macrogenics, Inc. | Composition and method of treating cancer with an anti-uroplakin ib antibody |
US8324369B2 (en) | 2007-11-30 | 2012-12-04 | Baylor College Of Medicine | Dendritic cell vaccine compositions and uses of same |
WO2010046422A2 (en) | 2008-10-22 | 2010-04-29 | Basf Se | Use of auxin type herbicides on cultivated plants |
WO2010046423A2 (en) | 2008-10-22 | 2010-04-29 | Basf Se | Use of sulfonylurea herbicides on cultivated plants |
WO2010106163A1 (en) | 2009-03-20 | 2010-09-23 | Basf Plant Science Company Gmbh | Nematode-resistant transgenic plants |
DE112010001772T5 (en) | 2009-03-20 | 2012-10-18 | Basf Plant Science Company Gmbh | NEMATODRESISTENT TRANSGENIC PLANTS |
US9808504B2 (en) | 2009-09-22 | 2017-11-07 | Yale University | Immunogenic epitopes as targets for universal cancer vaccines |
WO2011062962A2 (en) | 2009-11-17 | 2011-05-26 | The Trustees Of The University Of Pennsylvania | Smndelta7 degron: novel compositions and methods of use |
WO2011104153A1 (en) | 2010-02-23 | 2011-09-01 | Basf Plant Science Company Gmbh | Nematode-resistant transgenic plants |
US9574204B2 (en) | 2010-07-01 | 2017-02-21 | E I Dupont De Nemours And Company | Plant seeds with altered storage compound levels, related constructs and methods involving genes encoding PAE and PAE-like polypeptides |
WO2012003207A3 (en) * | 2010-07-01 | 2012-02-16 | E. I. Du Pont De Nemours And Company | Plant seeds with altered storage compound levels, related constructs and methods involving genes encoding pae and pae-like polypeptides |
US9970005B2 (en) | 2010-10-29 | 2018-05-15 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) |
US11932854B2 (en) | 2010-10-29 | 2024-03-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) |
US9260471B2 (en) | 2010-10-29 | 2016-02-16 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) |
US11193126B2 (en) | 2010-10-29 | 2021-12-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) |
EP3214091A1 (en) | 2010-12-09 | 2017-09-06 | The Trustees of The University of Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
WO2012079000A1 (en) | 2010-12-09 | 2012-06-14 | The Trustees Of The University Of Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
EP3660029A1 (en) | 2010-12-09 | 2020-06-03 | The Trustees of The University of Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
EP3305798A1 (en) | 2010-12-09 | 2018-04-11 | The Trustees of The University of Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
US11180550B2 (en) | 2011-01-18 | 2021-11-23 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating cancer |
US9402865B2 (en) | 2011-01-18 | 2016-08-02 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating cancer |
US10457729B2 (en) | 2011-01-18 | 2019-10-29 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating cancer |
WO2013055420A2 (en) | 2011-07-12 | 2013-04-18 | Philadelphia Health & Education Corporation | Novel clostridium difficile dna vaccine |
US9834612B2 (en) | 2011-07-22 | 2017-12-05 | The Research Foundation Of State University Of New York | Antibodies to the B12-transcobalamin receptor |
EP3549611A1 (en) | 2011-07-29 | 2019-10-09 | The Trustees of the University of Pennsylvania | Switch costimulatory receptors |
EP3915588A1 (en) | 2011-07-29 | 2021-12-01 | The Trustees of the University of Pennsylvania | Switch costimulatory receptors |
US10981969B2 (en) | 2011-07-29 | 2021-04-20 | The Trustees Of The University Of Pennsylvania | Switch costimulatory receptors |
US10266580B2 (en) | 2011-09-22 | 2019-04-23 | The Trustees Of The University Of Pennsylvania | Universal immune receptor expressed by T cells for the targeting of diverse and multiple antigens |
US11041012B2 (en) | 2011-09-22 | 2021-06-22 | The Trustees Of The University Of Pennsylvania | Universal immune receptor expressed by T cells for the targeting of diverse and multiple antigens |
US11912753B2 (en) | 2011-09-22 | 2024-02-27 | The Trustees Of The University Of Pennsylvania | Universal immune receptor expressed by T cells for the targeting of diverse and multiple antigens |
US9708384B2 (en) | 2011-09-22 | 2017-07-18 | The Trustees Of The University Of Pennsylvania | Universal immune receptor expressed by T cells for the targeting of diverse and multiple antigens |
WO2013050410A1 (en) | 2011-10-04 | 2013-04-11 | Bayer Intellectual Property Gmbh | RNAi FOR THE CONTROL OF FUNGI AND OOMYCETES BY INHIBITING SACCHAROPINE DEHYDROGENASE GENE |
US9272002B2 (en) | 2011-10-28 | 2016-03-01 | The Trustees Of The University Of Pennsylvania | Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting |
US9422351B2 (en) | 2011-11-03 | 2016-08-23 | The Trustees Of The University Of Pennsylvania | Isolated B7-H4 specific compositions and methods of use thereof |
WO2013067492A1 (en) | 2011-11-03 | 2013-05-10 | The Trustees Of The University Of Pennsylvania | Isolated b7-h4 specific compositions and methods of use thereof |
US10961288B2 (en) | 2011-11-03 | 2021-03-30 | The Trustees Of The University Of Pennsylvania | Isolated B7-H4 specific compositions and methods of use thereof |
US9279008B2 (en) | 2011-11-03 | 2016-03-08 | The Trustees Of The University Of Pennsylvania | Isolated B7-H4 specific compositions and methods of use thereof |
US10259849B2 (en) | 2011-11-03 | 2019-04-16 | The Trustees Of The University Of Pennsylvania | Isolated B7-H4 specific compositions and methods of use thereof |
US9790267B2 (en) | 2011-11-08 | 2017-10-17 | The Trustees Of The University Of Pennsylvania | Glypican-3-specific antibody and uses thereof |
US10808225B2 (en) | 2011-11-23 | 2020-10-20 | The Trustees Of The University Of Pennsylvania | Use of PDL1 expressing cells to convert T cells into regulatory T cells |
EP3696262A1 (en) | 2011-11-23 | 2020-08-19 | The Trustees Of The University Of Pennsylvania | Use of pdl1 expressing cells to convert t cells into regulatory t cells |
WO2013078230A1 (en) | 2011-11-23 | 2013-05-30 | The Trustees Of The University Of Pennsylvania | Use of pdl1 expressing cells to convert t cells into regulatory t cells |
US9644179B2 (en) | 2011-11-23 | 2017-05-09 | The Trustees Of The University Of Pennsylvania | Use of PDL1 expressing cells to convert T cells into regulatory T cells |
US10501519B2 (en) | 2012-02-22 | 2019-12-10 | The Trustees Of The University Of Pennsylvania | Use of the CD2 signaling domain in second-generation chimeric antigen receptors |
US11299536B2 (en) | 2012-02-22 | 2022-04-12 | The Trustees Of The University Of Pennsylvania | Compositions and methods for generating a persisting population of T cells useful for the treatment of cancer |
US10040846B2 (en) | 2012-02-22 | 2018-08-07 | The Trustees Of The University Of Pennsylvania | Compositions and methods for generating a persisting population of T cells useful for the treatment of cancer |
EP4230647A1 (en) | 2012-02-22 | 2023-08-23 | The Trustees of the University of Pennsylvania | Use of icos-based cars to enhance antitumor activity and car persistence |
US10800840B2 (en) | 2012-02-22 | 2020-10-13 | The Trustees Of The University Of Pennsylvania | Compositions and methods for generating a persisting population of T cells useful for the treatment of cancer |
US9783591B2 (en) | 2012-02-22 | 2017-10-10 | The Trustees Of The University Of Pennsylvania | Use of the CD2 signaling domain in second-generation chimeric antigen receptors |
WO2013126733A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of University Of Pennsylvania | Use of icos-based cars to enhance antitumor activity and car persistence |
EP4275699A2 (en) | 2012-02-22 | 2023-11-15 | The Trustees of the University of Pennsylvania | Use of the cd2 signaling domain in second-generation chimeric antigen receptors |
US11597754B2 (en) | 2012-02-22 | 2023-03-07 | The Trustees Of The University Of Pennsylvania | Use of the CD2 signaling domain in second-generation chimeric antigen receptors |
WO2013126729A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Use of the cd2 signaling domain in second-generation chimeric antigen receptors |
EP3747898A1 (en) | 2012-02-22 | 2020-12-09 | The Trustees of the University of Pennsylvania | Use of icos-based cars to enhance antitumor activity and car persistence |
EP3699284A1 (en) | 2012-07-05 | 2020-08-26 | The Trustees of the University of Pennsylvania | U1 snrnp regulates gene expression and modulates oncogenicity |
EP4148135A1 (en) | 2012-07-05 | 2023-03-15 | The Trustees of the University of Pennsylvania | U1 snrnp regulates gene expression and modulates oncogenicity |
EP3584256A1 (en) | 2012-07-13 | 2019-12-25 | The Trustees Of The University Of Pennsylvania | Methods of assessing the suitability of transduced t cells for administration |
US9572836B2 (en) | 2012-07-13 | 2017-02-21 | The Trustees Of The University Of Pennsylvania | Methods for assessing the suitability of transduced T cells for administration |
US10696749B2 (en) | 2012-07-13 | 2020-06-30 | The Trustees Of The University Of Pennsylvania | Enhancing activity of CAR T cells by co-introducing a bispecific antibody |
US11795240B2 (en) | 2012-07-13 | 2023-10-24 | The Trustees Of The University Of Pennsylvania | Enhancing activity of CAR T cells by co-introducing a bispecific antibody |
EP3730512A1 (en) | 2012-07-13 | 2020-10-28 | The Trustees of the University of Pennsylvania | Enhancing activity of car t cells by co-introducing a bispecific antibody |
US9765156B2 (en) | 2012-07-13 | 2017-09-19 | The Trustees Of The University Of Pennsylvania | Enhancing activity of CAR T cells by co-introducing a bispecific antibody |
US9937205B2 (en) | 2012-09-04 | 2018-04-10 | The Trustees Of The University Of Pennsylvania | Inhibition of diacylglycerol kinase to augment adoptive T cell transfer |
US11931380B2 (en) | 2012-09-04 | 2024-03-19 | The Trustees Of The University Of Pennsylvania | Inhibition of diacylglycerol kinase to augment adoptive T cell transfer |
US11718685B2 (en) | 2012-10-01 | 2023-08-08 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeting stromal cells for the treatment of cancer |
US10329355B2 (en) | 2012-10-01 | 2019-06-25 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeting stromal cells for the treatment of cancer |
WO2014053395A1 (en) | 2012-10-01 | 2014-04-10 | Basf Se | Use of n-thio-anthranilamide compounds on cultivated plants |
US9365641B2 (en) | 2012-10-01 | 2016-06-14 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeting stromal cells for the treatment of cancer |
US10844117B2 (en) | 2012-10-05 | 2020-11-24 | The Trustees Of The University Of Pennsylvania | Human alpha-folate receptor chimeric antigen receptor |
US9598489B2 (en) | 2012-10-05 | 2017-03-21 | The Trustees Of The Univeristy Of Pennsylvania | Human alpha-folate receptor chimeric antigen receptor |
WO2014090765A1 (en) | 2012-12-12 | 2014-06-19 | Bayer Cropscience Ag | Use of 1-[2-fluoro-4-methyl-5-(2,2,2-trifluoroethylsulfinyl)phenyl]-5-amino-3-trifluoromethyl)-1 h-1,2,4 tfia zole for controlling nematodes in nematode-resistant crops |
US9834610B2 (en) | 2013-01-31 | 2017-12-05 | Thomas Jefferson University | Fusion proteins for modulating regulatory and effector T cells |
WO2014130657A1 (en) | 2013-02-20 | 2014-08-28 | The Trustees Of The University Of Pennsylvania | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor |
EP3626741A1 (en) | 2013-02-20 | 2020-03-25 | The Trustees Of The University Of Pennsylvania | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor |
EP3744736A1 (en) | 2013-02-20 | 2020-12-02 | Novartis AG | Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells |
WO2014130635A1 (en) | 2013-02-20 | 2014-08-28 | Novartis Ag | Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells |
US9839677B2 (en) | 2013-03-01 | 2017-12-12 | Wake Forest University Health Sciences | Systemic gene replacement therapy for treatment of X-linked myotubular myopathy (XLMTM) |
US11564977B2 (en) | 2013-03-01 | 2023-01-31 | Wake Forest University Health Sciences | Systemic gene replacement therapy for treatment of X-linked myotubular myopathy (XLMTM) |
US9895426B2 (en) | 2013-03-01 | 2018-02-20 | Wake Forest University Health Sciences | Systemic gene replacement therapy for treatment of X-linked myotubular myopathy (XLMTM) |
US9415120B2 (en) | 2013-03-01 | 2016-08-16 | Wake Forest University Health Sciences | Systemic gene replacement therapy for treatment of X-linked MyoTubular Myopathy (XLMTM) |
US8957044B2 (en) | 2013-03-01 | 2015-02-17 | Wake Forest University Health Sciences | Systemic gene replacement therapy for treatment of X-linked myotubular myopathy (XLMTM) |
EP3623380A1 (en) | 2013-03-15 | 2020-03-18 | Michael C. Milone | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
US9446105B2 (en) | 2013-03-15 | 2016-09-20 | The Trustees Of The University Of Pennsylvania | Chimeric antigen receptor specific for folate receptor β |
WO2014153270A1 (en) | 2013-03-16 | 2014-09-25 | Novartis Ag | Treatment of cancer using humanized anti-cd19 chimeric antigen receptor |
EP4067382A1 (en) | 2013-03-16 | 2022-10-05 | Novartis AG | Treatment of cancer using humanized anti-cd19 chimeric antigen receptor |
EP3539986A1 (en) | 2013-03-16 | 2019-09-18 | Novartis AG | Treatment of cancer using humanized anti-cd19 chimeric antigen receptor |
WO2015090230A1 (en) | 2013-12-19 | 2015-06-25 | Novartis Ag | Human mesothelin chimeric antigen receptors and uses thereof |
EP4026909A1 (en) | 2013-12-19 | 2022-07-13 | Novartis AG | Human mesothelin chimeric antigen receptors and uses thereof |
WO2015090229A1 (en) | 2013-12-20 | 2015-06-25 | Novartis Ag | Regulatable chimeric antigen receptor |
WO2015112626A1 (en) | 2014-01-21 | 2015-07-30 | June Carl H | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules |
EP4303229A2 (en) | 2014-01-21 | 2024-01-10 | Novartis AG | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules |
WO2015116178A1 (en) | 2014-01-31 | 2015-08-06 | Thomas Jefferson University | Fusion proteins for modulating regulatory and effector t cells |
EP3811970A1 (en) | 2014-03-15 | 2021-04-28 | Novartis AG | Regulatable chimeric antigen receptor |
WO2015142675A2 (en) | 2014-03-15 | 2015-09-24 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
WO2015157252A1 (en) | 2014-04-07 | 2015-10-15 | BROGDON, Jennifer | Treatment of cancer using anti-cd19 chimeric antigen receptor |
EP3888674A1 (en) | 2014-04-07 | 2021-10-06 | Novartis AG | Treatment of cancer using anti-cd19 chimeric antigen receptor |
WO2015168613A2 (en) | 2014-05-02 | 2015-11-05 | The Trustees Of The University Of Pennsylvania | Compositions and methods of chimeric autoantibody receptor t cells |
EP4008725A1 (en) | 2014-05-02 | 2022-06-08 | The Trustees of the University of Pennsylvania | Compositions and methods of chimeric autoantibody receptor t cells |
EP3791891A1 (en) | 2014-07-17 | 2021-03-17 | Brian J. Czerniecki | Identification of immunogenic mhc class ii peptides for immune-based therapy |
WO2016011432A2 (en) | 2014-07-17 | 2016-01-21 | Czerniecki Brian J | Identification of immunogenic mhc class ii peptides for immune-based therapy |
WO2016014553A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
EP3722316A1 (en) | 2014-07-21 | 2020-10-14 | Novartis AG | Treatment of cancer using a cd33 chimeric antigen receptor |
WO2016014565A2 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Treatment of cancer using humanized anti-bcma chimeric antigen receptor |
WO2016014530A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Combinations of low, immune enhancing. doses of mtor inhibitors and cars |
EP3660042A1 (en) | 2014-07-31 | 2020-06-03 | Novartis AG | Subset-optimized chimeric antigen receptor-containing t-cells |
EP4205749A1 (en) | 2014-07-31 | 2023-07-05 | Novartis AG | Subset-optimized chimeric antigen receptor-containing cells |
WO2016025880A1 (en) | 2014-08-14 | 2016-02-18 | Novartis Ag | Treatment of cancer using gfr alpha-4 chimeric antigen receptor |
US10851149B2 (en) | 2014-08-14 | 2020-12-01 | The Trustees Of The University Of Pennsylvania | Treatment of cancer using GFR α-4 chimeric antigen receptor |
EP3712171A1 (en) | 2014-08-19 | 2020-09-23 | Novartis AG | Treatment of cancer using a cd123 chimeric antigen receptor |
WO2016044605A1 (en) | 2014-09-17 | 2016-03-24 | Beatty, Gregory | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
EP3967709A1 (en) | 2014-09-17 | 2022-03-16 | Novartis AG | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
WO2016057705A1 (en) | 2014-10-08 | 2016-04-14 | Novartis Ag | Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof |
WO2016090034A2 (en) | 2014-12-03 | 2016-06-09 | Novartis Ag | Methods for b cell preconditioning in car therapy |
WO2016091674A1 (en) | 2014-12-12 | 2016-06-16 | Basf Se | Use of cyclaniliprole on cultivated plants |
WO2016098078A2 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Dimerization switches and uses thereof |
EP4036109A2 (en) | 2014-12-29 | 2022-08-03 | Novartis AG | Methods of making chimeric antigen receptor-expressing cells |
US11919959B2 (en) | 2015-01-21 | 2024-03-05 | Cancer Research Technology Limited | Inhibitors of the interaction between CLEC14A and multimerin-2 for inhibition of angiogenesis |
US10808031B2 (en) | 2015-01-21 | 2020-10-20 | Cancer Research Technology Limited | Inhibitors of the interaction between CLEC14A and multimerin-2 for inhibition of angiogenesis |
WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
US11679132B2 (en) | 2015-02-06 | 2023-06-20 | National University Of Singapore | Methods for enhancing efficacy of therapeutic immune cells |
EP4091616A1 (en) | 2015-02-27 | 2022-11-23 | iCell Gene Therapeutics LLC | Chimeric antigen receptors (car) targeting hematologic malignancies, compositions and methods of use thereof |
WO2016138491A1 (en) | 2015-02-27 | 2016-09-01 | Icell Gene Therapeutics Llc | Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof |
WO2016140910A2 (en) | 2015-03-04 | 2016-09-09 | University Of Rochester | Compositions and methods of using anti-mullerian hormone for treatment of infertility |
US11219675B2 (en) | 2015-03-13 | 2022-01-11 | Syz Cell Therapy Co. | Methods of cancer treatment using activated T cells |
US11229689B2 (en) | 2015-03-13 | 2022-01-25 | Syz Cell Therapy Co. | Methods of cancer treatment using activated T cells |
US10011658B2 (en) | 2015-04-03 | 2018-07-03 | Eureka Therapeutics, Inc. | Constructs targeting AFP peptide/MHC complexes and uses thereof |
WO2016164305A1 (en) | 2015-04-06 | 2016-10-13 | Subdomain, Llc | De novo binding domain containing polypeptides and uses thereof |
EP3903804A1 (en) | 2015-04-06 | 2021-11-03 | Subdomain, LLC | De novo binding domain containing polypeptides and uses thereof |
WO2016164308A1 (en) | 2015-04-06 | 2016-10-13 | Subdomain, Llc | De novo binding domain containing polypeptides and uses thereof |
WO2016162371A1 (en) | 2015-04-07 | 2016-10-13 | Basf Agrochemical Products B.V. | Use of an insecticidal carboxamide compound against pests on cultivated plants |
WO2016164580A1 (en) | 2015-04-07 | 2016-10-13 | Novartis Ag | Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives |
EP4056588A1 (en) | 2015-04-08 | 2022-09-14 | Novartis AG | Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car)- expressing cell |
WO2016164731A2 (en) | 2015-04-08 | 2016-10-13 | Novartis Ag | Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell |
EP4234685A2 (en) | 2015-04-17 | 2023-08-30 | Novartis AG | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
WO2016168595A1 (en) | 2015-04-17 | 2016-10-20 | Barrett David Maxwell | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
WO2016170484A1 (en) | 2015-04-21 | 2016-10-27 | Novartis Ag | Rna-guided gene editing system and uses thereof |
WO2016172583A1 (en) | 2015-04-23 | 2016-10-27 | Novartis Ag | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
WO2016174652A1 (en) | 2015-04-30 | 2016-11-03 | Technion Research & Development Foundation Limited | Chimeric antigen receptors and methods of their use |
WO2016178996A1 (en) | 2015-05-01 | 2016-11-10 | The Regents Of The University Of California | Glycan-dependent immunotherapeutic molecules |
EP4088732A1 (en) | 2015-05-01 | 2022-11-16 | The Regents of The University of California | Glycan-dependent immunotherapeutic molecules |
WO2016187349A1 (en) | 2015-05-18 | 2016-11-24 | Tcr2, Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
US10358474B2 (en) | 2015-05-18 | 2019-07-23 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
US10358473B2 (en) | 2015-05-18 | 2019-07-23 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
EP3466967A1 (en) | 2015-05-18 | 2019-04-10 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
US10442849B2 (en) | 2015-05-18 | 2019-10-15 | Tcr2 Therabeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
US11028142B2 (en) | 2015-05-18 | 2021-06-08 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
EP3770168A1 (en) | 2015-05-18 | 2021-01-27 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
US10954311B2 (en) | 2015-05-21 | 2021-03-23 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
WO2016210293A1 (en) | 2015-06-25 | 2016-12-29 | Icell Gene Therapeutics Llc | CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS OF USE THEREOF |
WO2017009853A1 (en) | 2015-07-16 | 2017-01-19 | Yeda Research And Development Co. Ltd. | Genetically modified anti-third party central memory t cells and use of same in immunotherapy |
WO2017015427A1 (en) | 2015-07-21 | 2017-01-26 | Novartis Ag | Methods for improving the efficacy and expansion of immune cells |
WO2017040195A1 (en) | 2015-08-28 | 2017-03-09 | The Trustees Of The University Of Pennsylvania | Methods and compositions for cells expressing a chimeric intracellular signaling molecule |
WO2017040930A2 (en) | 2015-09-03 | 2017-03-09 | The Trustees Of The University Of Pennsylvania | Biomarkers predictive of cytokine release syndrome |
US10738099B2 (en) | 2015-09-22 | 2020-08-11 | The Trustees Of The University Of Pennsylvania | Method of redirecting T cells to treat HIV infection |
US11421013B2 (en) | 2015-10-23 | 2022-08-23 | Eureka Therapeutics, Inc. | Antibody/T-cell receptor chimeric constructs and uses thereof |
US10822389B2 (en) | 2015-10-23 | 2020-11-03 | Eureka Therapeutics, Inc. | Antibody/T-cell receptor chimeric constructs and uses thereof |
EP3842450A1 (en) | 2015-10-23 | 2021-06-30 | Eureka Therapeutics, Inc. | Antibody/t-cell receptor chimeric constructs and uses thereof |
WO2017070608A1 (en) | 2015-10-23 | 2017-04-27 | Eureka Therapeutics, Inc. | Antibody/t-cell receptor chimeric constructs and uses thereof |
US10098951B2 (en) | 2015-10-23 | 2018-10-16 | Eureka Therapeutics, Inc. | Antibody/T-cell receptor chimeric constructs and uses thereof |
US10464988B2 (en) | 2015-10-23 | 2019-11-05 | Eureka Therapeutics, Inc. | Antibody/T-cell receptor chimeric constructs and uses thereof |
WO2017075421A1 (en) | 2015-10-29 | 2017-05-04 | Temple University-Of The Commonwealth System Of Higher Education | Modification of 3' terminal ends of nucleic acids by dna polymerase theta |
US10508143B1 (en) | 2015-10-30 | 2019-12-17 | Aleta Biotherapeutics Inc. | Compositions and methods for treatment of cancer |
US10066023B2 (en) | 2015-10-30 | 2018-09-04 | Aleta Biotherapeutics Inc. | Compositions and methods for tumor transduction |
US11807691B2 (en) | 2015-10-30 | 2023-11-07 | Aleta Biotherapeutics Inc. | Compositions and methods for treatment of cancer |
US10072094B2 (en) | 2015-10-30 | 2018-09-11 | Aleta Biotherapeutics Inc. | Compositions and methods for tumor transduction |
US10669349B2 (en) | 2015-10-30 | 2020-06-02 | Aleta Biotherapeutics Inc. | Compositions and methods for treatment of cancer |
US11059904B2 (en) | 2015-10-30 | 2021-07-13 | Aleta Biotherapeutics Inc. | Compositions and methods for tumor transduction |
EP3708587A1 (en) | 2015-11-27 | 2020-09-16 | Cartherics Pty. Ltd. | Genetically modified cells and uses thereof |
EP3708588A1 (en) | 2015-11-27 | 2020-09-16 | Cartherics Pty. Ltd. | Genetically modified cells and uses thereof |
WO2017088012A1 (en) | 2015-11-27 | 2017-06-01 | Cartherics Pty. Ltd. | Genetically modified cells and uses thereof |
WO2017095823A1 (en) | 2015-11-30 | 2017-06-08 | The Regents Of The University Of California | Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen |
WO2017112741A1 (en) | 2015-12-22 | 2017-06-29 | Novartis Ag | Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy |
WO2017117112A1 (en) | 2015-12-28 | 2017-07-06 | Novartis Ag | Methods of making chimeric antigen receptor -expressing cells |
WO2017118726A1 (en) | 2016-01-06 | 2017-07-13 | Lonza Ltd | Inhibition of protein degradation for improved production |
US11441146B2 (en) | 2016-01-11 | 2022-09-13 | Christiana Care Health Services, Inc. | Compositions and methods for improving homogeneity of DNA generated using a CRISPR/Cas9 cleavage system |
WO2017149515A1 (en) | 2016-03-04 | 2017-09-08 | Novartis Ag | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore |
US11613900B2 (en) | 2016-03-10 | 2023-03-28 | Lonza Ltd | Customizable facility |
US10689873B2 (en) | 2016-03-10 | 2020-06-23 | Lonza Ltd | Customizable facility |
US11236520B2 (en) | 2016-03-10 | 2022-02-01 | Lonza Ltd | Customizable facility |
US11377865B2 (en) | 2016-03-10 | 2022-07-05 | Lonza Ltd | Customizable facility |
WO2017172981A2 (en) | 2016-03-29 | 2017-10-05 | University Of Southern California | Chimeric antigen receptors targeting cancer |
WO2017178526A1 (en) | 2016-04-14 | 2017-10-19 | Lonza Ltd | Compositions and methods for the detection of host cell proteins |
EP3683579A1 (en) | 2016-04-14 | 2020-07-22 | Lonza Ltd | Compositions and methods for the detection of host cell proteins |
EP4219721A2 (en) | 2016-04-15 | 2023-08-02 | Novartis AG | Compositions and methods for selective protein expression |
WO2017181119A2 (en) | 2016-04-15 | 2017-10-19 | Novartis Ag | Compositions and methods for selective protein expression |
WO2017181101A1 (en) | 2016-04-15 | 2017-10-19 | The Trustees Of The University Of Pennsylvania | Compositions and methods of chimeric alloantigen receptor t cells |
WO2017190001A1 (en) | 2016-04-29 | 2017-11-02 | The Regents Of The University Of Colorado, A Body Corporate | Compounds and compositions useful for treating metabolic syndrome, and methods using same |
US11434474B2 (en) | 2016-05-03 | 2022-09-06 | Lonza Ltd | Modulation of lipid metabolism for protein production |
US10655111B2 (en) | 2016-05-03 | 2020-05-19 | Lonza Ltd. | Modulation of lipid metabolism for protein production |
WO2017191165A1 (en) | 2016-05-03 | 2017-11-09 | Lonza Ltd | Modulation of lipid metabolism for protein production |
US11453716B2 (en) | 2016-05-20 | 2022-09-27 | Harpoon Therapeutics, Inc. | Single domain serum albumin binding protein |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
WO2017210617A2 (en) | 2016-06-02 | 2017-12-07 | Porter, David, L. | Therapeutic regimens for chimeric antigen receptor (car)- expressing cells |
WO2017214333A1 (en) | 2016-06-08 | 2017-12-14 | Intrexon Corporation | Cd33 specific chimeric antigen receptors |
WO2018013918A2 (en) | 2016-07-15 | 2018-01-18 | Novartis Ag | Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor |
WO2018014122A1 (en) | 2016-07-18 | 2018-01-25 | Helix Biopharma Corp. | Car immune cells directed to carcinoembryonic antigen related cell adhesion molecule 6 to treat cancer |
WO2018023025A1 (en) | 2016-07-28 | 2018-02-01 | Novartis Ag | Combination therapies of chimeric antigen receptors adn pd-1 inhibitors |
WO2018026819A2 (en) | 2016-08-01 | 2018-02-08 | Novartis Ag | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule |
US11242376B2 (en) | 2016-08-02 | 2022-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
US10669518B2 (en) | 2016-08-02 | 2020-06-02 | Lonza Ltd | Method and system for providing buffer solutions |
WO2018026953A1 (en) | 2016-08-02 | 2018-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
WO2018026956A1 (en) | 2016-08-02 | 2018-02-08 | Lonza Ltd | Method and system for providing buffer solutions |
US11898137B2 (en) | 2016-08-02 | 2024-02-13 | Lonza Ltd | Method and system for providing buffer solutions |
WO2018031858A1 (en) | 2016-08-12 | 2018-02-15 | Lonza Ltd | Proteomic analysis of host cell proteins |
WO2018053542A1 (en) | 2016-09-19 | 2018-03-22 | University Of Southern California | Non-radioactive cytotoxicity assays |
EP4115951A1 (en) | 2016-10-04 | 2023-01-11 | Precision Biosciences, Inc. | Co-stimulatory domains for use in genetically-modified cells |
US10800833B2 (en) | 2016-10-04 | 2020-10-13 | Precision Biosciences, Inc. | Co-stimulatory domains for use in genetically-modified cells |
US11286291B2 (en) | 2016-10-04 | 2022-03-29 | Precision Biosciences, Inc. | Co-stimulatory domains for use in genetically-modified cells |
WO2018067697A1 (en) | 2016-10-04 | 2018-04-12 | Precision Biosciences, Inc. | Co-stimulatory domains for use in genetically-modified cells |
EP3757120A1 (en) | 2016-10-04 | 2020-12-30 | Precision Biosciences, Inc. | Co-stimulatory domains for use in genetically-modified cells |
EP3848392A1 (en) | 2016-10-07 | 2021-07-14 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
WO2018067992A1 (en) | 2016-10-07 | 2018-04-12 | Novartis Ag | Chimeric antigen receptors for the treatment of cancer |
US11085021B2 (en) | 2016-10-07 | 2021-08-10 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
US10208285B2 (en) | 2016-10-07 | 2019-02-19 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
WO2018067993A1 (en) | 2016-10-07 | 2018-04-12 | TCR2 Therapeutics Inc. | Compositions and methods for t-cell receptors reprogramming using fusion proteins |
US11377638B2 (en) | 2016-10-07 | 2022-07-05 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
WO2018083606A1 (en) | 2016-11-01 | 2018-05-11 | Novartis Ag | Methods and compositions for enhancing gene editing |
US11945865B2 (en) | 2016-11-22 | 2024-04-02 | National University Of Singapore | Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies |
US11851491B2 (en) | 2016-11-22 | 2023-12-26 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
WO2018098365A2 (en) | 2016-11-22 | 2018-05-31 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
US11440958B2 (en) | 2016-11-22 | 2022-09-13 | National University Of Singapore | Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies |
US10849973B2 (en) | 2016-11-23 | 2020-12-01 | Harpoon Therapeutics, Inc. | Prostate specific membrane antigen binding protein |
US10844134B2 (en) | 2016-11-23 | 2020-11-24 | Harpoon Therapeutics, Inc. | PSMA targeting trispecific proteins and methods of use |
WO2018119298A1 (en) | 2016-12-21 | 2018-06-28 | TCR2 Therapeutics Inc. | Engineered t cells for the treatment of cancer |
WO2018127585A1 (en) | 2017-01-06 | 2018-07-12 | Txcell | Monospecific regulatory t cell population with cytotoxicity for b cells |
WO2018127584A1 (en) | 2017-01-06 | 2018-07-12 | Txcell | Monospecific regulatory t cell population with cytotoxicity for b cells |
EP3346001A1 (en) | 2017-01-06 | 2018-07-11 | TXCell | Monospecific regulatory t cell population with cytotoxicity for b cells |
WO2018132494A1 (en) | 2017-01-10 | 2018-07-19 | Intrexon Corporation | Modulating expression of polypeptides via new gene switch expression systems |
WO2018132390A1 (en) | 2017-01-10 | 2018-07-19 | Christiana Care Health Services, Inc. | Methods for in vitro site-directed mutagenesis using gene editing technologies |
US11274157B2 (en) | 2017-01-12 | 2022-03-15 | Eureka Therapeutics, Inc. | Constructs targeting histone H3 peptide/MHC complexes and uses thereof |
WO2018134824A1 (en) | 2017-01-18 | 2018-07-26 | Yeda Research And Development Co. Ltd. | Genetically modified veto cells and use of same in immunotherapy |
WO2018140725A1 (en) | 2017-01-26 | 2018-08-02 | Novartis Ag | Cd28 compositions and methods for chimeric antigen receptor therapy |
EP4043485A1 (en) | 2017-01-26 | 2022-08-17 | Novartis AG | Cd28 compositions and methods for chimeric antigen receptor therapy |
EP4194473A1 (en) | 2017-02-08 | 2023-06-14 | Cellular Biomedicine Group Inc. | Construction of chimeric antigen receptor targeting cd20 antigen and activity identification of engineered t cells thereof |
WO2018145649A1 (en) | 2017-02-08 | 2018-08-16 | 西比曼生物科技(上海)有限公司 | Construction of chimeric antigen receptor targeting cd20 antigen and activity identification of engineered t cells thereof |
WO2018157072A1 (en) | 2017-02-27 | 2018-08-30 | Life Technologies Corporation | Expansion of populations of t cells by the use of modified serum free media |
US11597911B2 (en) | 2017-02-27 | 2023-03-07 | Life Technologies Corporation | Expansion of populations of T cells by the use of modified serum free media |
US11535668B2 (en) | 2017-02-28 | 2022-12-27 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
US10934336B2 (en) | 2017-04-13 | 2021-03-02 | The Trustees Of The University Of Pennsylvania | Use of gene editing to generate universal TCR re-directed T cells for adoptive immunotherapy |
US11447564B2 (en) | 2017-04-26 | 2022-09-20 | Eureka Therapeutics, Inc. | Constructs specifically recognizing glypican 3 and uses thereof |
US11613573B2 (en) | 2017-04-26 | 2023-03-28 | Eureka Therapeutics, Inc. | Chimeric antibody/T-cell receptor constructs and uses thereof |
WO2018200583A1 (en) | 2017-04-26 | 2018-11-01 | Eureka Therapeutics, Inc. | Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof |
US10822413B2 (en) | 2017-04-26 | 2020-11-03 | Eureka Therapeutics, Inc. | Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof |
WO2018201056A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
WO2018208837A1 (en) | 2017-05-08 | 2018-11-15 | Precision Biosciences, Inc. | Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof |
EP4029943A1 (en) | 2017-05-08 | 2022-07-20 | Precision Biosciences, Inc. | Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof |
US10730954B2 (en) | 2017-05-12 | 2020-08-04 | Harpoon Therapeutics, Inc. | MSLN targeting trispecific proteins and methods of use |
US11607453B2 (en) | 2017-05-12 | 2023-03-21 | Harpoon Therapeutics, Inc. | Mesothelin binding proteins |
WO2018232020A1 (en) | 2017-06-13 | 2018-12-20 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
WO2018232265A1 (en) | 2017-06-16 | 2018-12-20 | Lonza Ltd | Universal self-regulating mammalian cell line platform for the production of biologics |
WO2019007991A1 (en) | 2017-07-03 | 2019-01-10 | Universite De Strasbourg | Mtmr2-s polypeptide for use in the treatment of myopathies |
WO2019047899A1 (en) | 2017-09-06 | 2019-03-14 | 亘喜生物科技(上海)有限公司 | Universal chimeric antigen receptor t-cell preparation technique |
WO2019055853A1 (en) | 2017-09-15 | 2019-03-21 | Life Technologies Corporation | Compositions and methods for culturing and expanding cells |
US11814432B2 (en) | 2017-09-20 | 2023-11-14 | The University Of British Columbia | Anti-HLA-A2 antibodies, related chimeric antigen receptors, and uses thereof |
WO2019062817A1 (en) | 2017-09-27 | 2019-04-04 | 亘喜生物科技(上海)有限公司 | Engineered immune cell capable of inducing secretion of anti-cd47 antibody |
WO2019070856A1 (en) | 2017-10-03 | 2019-04-11 | Precision Biosciences, Inc. | Modified epidermal growth factor receptor peptides for use in genetically-modified cells |
EP4269560A2 (en) | 2017-10-03 | 2023-11-01 | Precision Biosciences, Inc. | Modified epidermal growth factor receptor peptides for use in genetically-modified cells |
US11215618B2 (en) | 2017-10-04 | 2022-01-04 | Hesperix SA | Articles and methods directed to personalized therapy of cancer |
WO2019070161A2 (en) | 2017-10-04 | 2019-04-11 | Opko Pharmaceuticals, Llc | Articles and methods directed to personalized therapy of cancer |
WO2019069125A1 (en) | 2017-10-06 | 2019-04-11 | Oslo Universitetssykehus Hf | Chimeric antigen receptors |
US11136403B2 (en) | 2017-10-13 | 2021-10-05 | Harpoon Therapeutics, Inc. | Trispecific proteins and methods of use |
US10927180B2 (en) | 2017-10-13 | 2021-02-23 | Harpoon Therapeutics, Inc. | B cell maturation antigen binding proteins |
WO2019084288A1 (en) | 2017-10-25 | 2019-05-02 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
WO2019089798A1 (en) | 2017-10-31 | 2019-05-09 | Novartis Ag | Anti-car compositions and methods |
WO2019092251A1 (en) | 2017-11-11 | 2019-05-16 | Universite De Strasbourg | Compositions and method for the treatment of x-linked centronuclear myopathy |
WO2019099440A1 (en) | 2017-11-14 | 2019-05-23 | Arcellx, Inc. | Multifunctional immune cell therapies |
WO2019099433A2 (en) | 2017-11-14 | 2019-05-23 | Arcellx, Inc. | D-domain containing polypeptides and uses thereof |
WO2019099639A1 (en) | 2017-11-15 | 2019-05-23 | Navartis Ag | Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies |
WO2019108900A1 (en) | 2017-11-30 | 2019-06-06 | Novartis Ag | Bcma-targeting chimeric antigen receptor, and uses thereof |
WO2019113050A1 (en) | 2017-12-05 | 2019-06-13 | Lonza Ltd | Methods of assaying tropolone |
WO2019129851A1 (en) | 2017-12-29 | 2019-07-04 | Cellectis | Method for improving production of car t cells |
WO2019136432A1 (en) | 2018-01-08 | 2019-07-11 | Novartis Ag | Immune-enhancing rnas for combination with chimeric antigen receptor therapy |
WO2019145711A1 (en) | 2018-01-23 | 2019-08-01 | Immetacyte Limited | Biomarker predictive of tumour infiltrating lymphocyte therapy and uses thereof |
EP4233883A2 (en) | 2018-01-23 | 2023-08-30 | Instil Bio (Uk) Limited | Biomarker predictive of tumour infiltrating lymphocyte therapy and uses thereof |
WO2019152660A1 (en) | 2018-01-31 | 2019-08-08 | Novartis Ag | Combination therapy using a chimeric antigen receptor |
EP3741853A1 (en) | 2018-02-02 | 2020-11-25 | Lonza Ltd. | Methods of cell selection and modifying cell metabolism |
WO2019152876A2 (en) | 2018-02-02 | 2019-08-08 | Lonza Ltd | Methods of cell selection and modifying cell metabolism |
US11396552B2 (en) | 2018-02-12 | 2022-07-26 | Diabetes-Free Inc. | Antagonistic anti-human CD40 monoclonal antibodies |
WO2019160956A1 (en) | 2018-02-13 | 2019-08-22 | Novartis Ag | Chimeric antigen receptor therapy in combination with il-15r and il15 |
US11485782B2 (en) | 2018-03-14 | 2022-11-01 | Beijing Xuanyi Pharmasciences Co., Ltd. | Anti-claudin 18.2 antibodies |
US11248208B2 (en) | 2018-03-30 | 2022-02-15 | Syz Cell Therapy Co. | Multiple antigen specific cell therapy methods |
US11142581B2 (en) | 2018-04-12 | 2021-10-12 | Cellular Biomedicine Group Hk Limited | BCMA-targeted chimeric antigen receptor as well as preparation method therefor and application thereof |
WO2019196713A1 (en) | 2018-04-12 | 2019-10-17 | 西比曼生物科技(香港)有限公司 | Bcma-targeted chimeric antigen receptor as well as preparation method therefor and application thereof |
US11390659B2 (en) | 2018-04-13 | 2022-07-19 | Syz Cell Therapy Co. | Methods of obtaining tumor-specific T cell receptors |
US11471519B2 (en) | 2018-04-13 | 2022-10-18 | Syz Cell Therapy Co. | Methods of cancer treatment using tumor antigen-specific T cells |
US11219676B2 (en) | 2018-04-13 | 2022-01-11 | Syz Cell Therapy Co. | Methods of cancer treatment using tumor antigen-specific T cells |
WO2019210153A1 (en) | 2018-04-27 | 2019-10-31 | Novartis Ag | Car t cell therapies with enhanced efficacy |
US10874750B2 (en) | 2018-04-30 | 2020-12-29 | Amicus Therapeutics, Inc. | Gene therapy constructs and methods of use |
WO2019213180A1 (en) | 2018-04-30 | 2019-11-07 | Amicus Therapeutics, Inc. | Gene therapy constructs and methods of use |
US11491243B2 (en) | 2018-04-30 | 2022-11-08 | Amicus Therapeutics, Inc. | Gene therapy constructs and methods of use |
WO2019213282A1 (en) | 2018-05-01 | 2019-11-07 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
WO2019217512A1 (en) | 2018-05-08 | 2019-11-14 | Life Technologies Corporation | Compositions and methods for culturing and expanding cells |
WO2019227003A1 (en) | 2018-05-25 | 2019-11-28 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
WO2019241426A1 (en) | 2018-06-13 | 2019-12-19 | Novartis Ag | Bcma chimeric antigen receptors and uses thereof |
WO2019241549A1 (en) | 2018-06-15 | 2019-12-19 | A2 Biotherapeutics, Inc. | Foxp3-expressing car-t regulatory cells |
WO2019243835A1 (en) | 2018-06-21 | 2019-12-26 | Immetacyte Limited | Chimeric growth factor receptors |
WO2020030979A2 (en) | 2018-08-10 | 2020-02-13 | Sangamo Therapeutics France | New car constructs comprising tnfr2 domains |
WO2020047501A1 (en) | 2018-08-30 | 2020-03-05 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
WO2020047452A2 (en) | 2018-08-31 | 2020-03-05 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
WO2020047449A2 (en) | 2018-08-31 | 2020-03-05 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
WO2020043899A1 (en) | 2018-08-31 | 2020-03-05 | Invectys | Chimeric antigen receptors against multiple hla-g isoforms |
US10815311B2 (en) | 2018-09-25 | 2020-10-27 | Harpoon Therapeutics, Inc. | DLL3 binding proteins and methods of use |
US11807692B2 (en) | 2018-09-25 | 2023-11-07 | Harpoon Therapeutics, Inc. | DLL3 binding proteins and methods of use |
WO2020069405A1 (en) | 2018-09-28 | 2020-04-02 | Novartis Ag | Cd22 chimeric antigen receptor (car) therapies |
WO2020069409A1 (en) | 2018-09-28 | 2020-04-02 | Novartis Ag | Cd19 chimeric antigen receptor (car) and cd22 car combination therapies |
US11097015B2 (en) | 2018-10-10 | 2021-08-24 | Amicus Therapeutics, Inc. | Disulfide bond stabilized polypeptide compositions and methods of use |
WO2020077114A2 (en) | 2018-10-10 | 2020-04-16 | Amicus Therapeutics, Inc. | Disulfide bond stabilized polypeptide compositions and methods of use |
WO2020081929A1 (en) | 2018-10-19 | 2020-04-23 | University Of Rochester | Immune modulators in combination with radiation treatment for advanced pancreatic cancer |
WO2020086627A1 (en) | 2018-10-22 | 2020-04-30 | University Of Rochester | Genome editing by directed non-homologous dna insertion using a retroviral integrase-cas9 fusion protein |
WO2020092455A2 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Car t cell transcriptional atlas |
US11130783B2 (en) | 2018-11-13 | 2021-09-28 | Regents Of The University Of Minnesota | CD40 targeted peptides and uses thereof |
WO2020102676A1 (en) | 2018-11-16 | 2020-05-22 | Celgene Corporation | Improved t cell manufacturing process |
WO2020102555A1 (en) | 2018-11-16 | 2020-05-22 | Memorial Sloan Kettering Cancer Center | Antibodies to mucin-16 and methods of use thereof |
EP4151722A1 (en) | 2018-11-16 | 2023-03-22 | Celgene Corporation | Improved t cell manufacturing process |
WO2020140007A1 (en) | 2018-12-28 | 2020-07-02 | University Of Rochester | Gene therapy for best1 dominant mutations |
WO2020150287A1 (en) | 2019-01-14 | 2020-07-23 | University Of Rochester | Targeted nuclear rna cleavage and polyadenylation with crispr-cas |
WO2020152451A1 (en) | 2019-01-22 | 2020-07-30 | Immetacyte Limited | Receptors providing targeted costimulation for adoptive cell therapy |
WO2020161186A1 (en) | 2019-02-08 | 2020-08-13 | Biontech Cell & Gene Therapies Gmbh | Chimeric antigen receptor-modified cells for the treatment of cldn6-expressing cancers |
WO2020172553A1 (en) | 2019-02-22 | 2020-08-27 | Novartis Ag | Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors |
WO2020185121A2 (en) | 2019-03-13 | 2020-09-17 | Общество С Ограниченной Ответственностью "Анабион" | Isolated alternative intracellular signalling domain of a chimeric antigen receptor and chimeric antigen receptor comprising said signalling domain |
US10934337B2 (en) | 2019-03-15 | 2021-03-02 | Cartesian Therapeutics, Inc. | Anti-BCMA chimeric antigen receptors |
US11220535B2 (en) | 2019-03-15 | 2022-01-11 | Cartesian Therapeutics, Inc. | Anti-BCMA chimeric antigen receptors |
WO2020188103A1 (en) | 2019-03-20 | 2020-09-24 | Centre National De La Recherche Scientifique | Amphiphysin / bin1 for the treatment of autosomal dominant centronuclear myopathy |
US11090336B2 (en) | 2019-03-27 | 2021-08-17 | The Trustees Of The University Of Pennsylvania | Tn-MUC1 chimeric antigen receptor (CAR) T cell therapy |
WO2020210678A1 (en) | 2019-04-12 | 2020-10-15 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
WO2020219742A1 (en) | 2019-04-24 | 2020-10-29 | Novartis Ag | Compositions and methods for selective protein degradation |
WO2020224606A1 (en) | 2019-05-07 | 2020-11-12 | 亘喜生物科技(上海)有限公司 | Engineered immune cell targeting bcma and use thereof |
US11840575B2 (en) | 2019-05-07 | 2023-12-12 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Engineered immune cells targeting BCMA and their uses thereof |
WO2021003442A1 (en) | 2019-07-02 | 2021-01-07 | M6P Therapeutics | Vector compositions and methods of using same for treatment of lysosomal storage disorders |
WO2021016453A1 (en) | 2019-07-23 | 2021-01-28 | University Of Rochester | Targeted rna cleavage with crispr-cas |
WO2021016608A1 (en) | 2019-07-25 | 2021-01-28 | Precision Biosciences, Inc. | Compositions and methods for sequential stacking of nucleic acid sequences into a genomic locus |
WO2021018311A1 (en) | 2019-08-01 | 2021-02-04 | 上海赛比曼生物科技有限公司 | Universal car-t cell and preparation and use thereof |
WO2021030182A1 (en) | 2019-08-09 | 2021-02-18 | A2 Biotherapeutics, Inc. | Bifunctional single variable domain t cell receptors and uses thereof |
WO2021032779A1 (en) | 2019-08-19 | 2021-02-25 | Universität Basel | Cell therapy methods |
WO2021035054A1 (en) | 2019-08-20 | 2021-02-25 | Precision Biosciences, Inc. | Lymphodepletion dosing regimens for cellular immunotherapies |
WO2021035170A1 (en) | 2019-08-21 | 2021-02-25 | Precision Biosciences, Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
EP3808766A1 (en) | 2019-10-15 | 2021-04-21 | Sangamo Therapeutics France | Chimeric antigen receptor specific for interleukin-23 receptor |
WO2021096868A1 (en) | 2019-11-12 | 2021-05-20 | A2 Biotherapeutics, Inc. | Engineered t cell receptors and uses thereof |
WO2021094461A1 (en) | 2019-11-14 | 2021-05-20 | Lonza Ltd | Methods of cell selection |
WO2021098882A1 (en) | 2019-11-21 | 2021-05-27 | 博生吉医药科技(苏州)有限公司 | Cd7-car-t cell and preparation and application thereof |
WO2021108661A2 (en) | 2019-11-26 | 2021-06-03 | Novartis Ag | Chimeric antigen receptors and uses thereof |
WO2021108613A1 (en) | 2019-11-26 | 2021-06-03 | Novartis Ag | Cd19 and cd22 chimeric antigen receptors and uses thereof |
US11254726B2 (en) | 2019-12-11 | 2022-02-22 | A2 Biotherapeutics, Inc. | LILRB1-based chimeric antigen receptor |
WO2021119489A1 (en) | 2019-12-11 | 2021-06-17 | A2 Biotherapeutics, Inc. | Lilrb1-based chimeric antigen receptor |
WO2021158964A1 (en) | 2020-02-07 | 2021-08-12 | University Of Rochester | Ribozyme-mediated rna assembly and expression |
WO2021158982A2 (en) | 2020-02-07 | 2021-08-12 | University Of Rochester | Targeted translation of rna with crispr-cas13 to enhance protein synthesis |
WO2021163618A1 (en) | 2020-02-14 | 2021-08-19 | Novartis Ag | Method of predicting response to chimeric antigen receptor therapy |
US11180563B2 (en) | 2020-02-21 | 2021-11-23 | Harpoon Therapeutics, Inc. | FLT3 binding proteins and methods of use |
WO2021173674A1 (en) | 2020-02-26 | 2021-09-02 | A2 Biotherapeutics, Inc. | Polypeptides targeting mage-a3 peptide-mhc complexes and methods of use thereof |
WO2021173995A2 (en) | 2020-02-27 | 2021-09-02 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
WO2021173985A2 (en) | 2020-02-27 | 2021-09-02 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
WO2021170071A1 (en) | 2020-02-28 | 2021-09-02 | Shanghai Henlius Biotech, Inc. | Anti-cd137 constructs, multispecific antibody and uses thereof |
WO2021170067A1 (en) | 2020-02-28 | 2021-09-02 | 上海复宏汉霖生物技术股份有限公司 | Anti-cd137 construct and use thereof |
WO2021186246A1 (en) | 2020-03-19 | 2021-09-23 | Trizell Ltd. | Temperature-responsive virus storage system |
WO2021186056A1 (en) | 2020-03-20 | 2021-09-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Chimeric antigen receptor specific for human cd45rc and uses thereof |
WO2021195519A1 (en) | 2020-03-27 | 2021-09-30 | University Of Rochester | Targeted destruction of viral rna by crispr-cas13 |
WO2021195525A1 (en) | 2020-03-27 | 2021-09-30 | University Of Rochester | Crispr-cas13 crrna arrays |
WO2021208750A1 (en) | 2020-04-16 | 2021-10-21 | 上海赛比曼生物科技有限公司 | Cd22-targeted chimeric antigen receptor, preparation method therefor and application thereof |
WO2021222576A1 (en) | 2020-05-01 | 2021-11-04 | A2 Biotherapeutics, Inc. | Pag1 fusion proteins and methods of making and using same |
WO2021238886A1 (en) | 2020-05-27 | 2021-12-02 | Staidson (Beijing) Biopharmaceuticals Co., Ltd. | Antibodies specifically recognizing nerve growth factor and uses thereof |
WO2021252635A1 (en) | 2020-06-11 | 2021-12-16 | A2 Biotherapeutics, Inc. | Compositions and methods for treating cancers |
WO2021252920A1 (en) | 2020-06-11 | 2021-12-16 | Novartis Ag | Zbtb32 inhibitors and uses thereof |
WO2022015916A1 (en) | 2020-07-15 | 2022-01-20 | University Of Rochester | Targeted rna cleavage with dcasl3-rnase fusion proteins |
WO2022011651A1 (en) | 2020-07-16 | 2022-01-20 | 上海交通大学 | Immunotherapy method of targeted chemokine and cytokine delivery by mesenchymal stem cell |
WO2022016114A1 (en) | 2020-07-17 | 2022-01-20 | Instill Bio (Uk) Limited | Chimeric molecules providing targeted costimulation for adoptive cell therapy |
WO2022016112A1 (en) | 2020-07-17 | 2022-01-20 | Instil Bio (Uk) Limited | Receptors providing targeted costimulation for adoptive cell therapy |
WO2022036068A1 (en) | 2020-08-13 | 2022-02-17 | A2 Biotherapeutics, Inc. | Gene fusions for control of genetically modified cells |
US11602544B2 (en) | 2020-08-20 | 2023-03-14 | A2 Biotherapeutics, Inc. | Compositions and methods for treating EGFR positive cancers |
US11433100B2 (en) | 2020-08-20 | 2022-09-06 | A2 Biotherapeutics, Inc. | Compositions and methods for treating ceacam positive cancers |
US11602543B2 (en) | 2020-08-20 | 2023-03-14 | A2 Biotherapeutics, Inc. | Compositions and methods for treating mesothelin positive cancers |
WO2022079308A1 (en) | 2020-10-16 | 2022-04-21 | Institut Pasteur | Chimeric constructs useful in vaccination and cancer therapy |
WO2022104061A1 (en) | 2020-11-13 | 2022-05-19 | Novartis Ag | Combination therapies with chimeric antigen receptor (car)-expressing cells |
WO2022105893A1 (en) | 2020-11-23 | 2022-05-27 | 博生吉医药科技(苏州)有限公司 | Preparation method and application of cd7-car-t cells |
WO2022123307A1 (en) | 2020-12-09 | 2022-06-16 | Takeda Pharmaceutical Company Limited | Compositions of guanylyl cyclase c (gcc) antigen binding agents and methods of use thereof |
WO2022123316A1 (en) | 2020-12-09 | 2022-06-16 | Takeda Pharmaceutical Company Limited | Compositions of guanylyl cyclase c (gcc) antigen binding agents and methods of use thereof |
WO2022147463A2 (en) | 2020-12-31 | 2022-07-07 | Alamar Biosciences, Inc. | Binder molecules with high affinity and/ or specificity and methods of making and use thereof |
WO2022151960A1 (en) | 2021-01-13 | 2022-07-21 | 博生吉医药科技(苏州)有限公司 | B7-h3 chimeric antigen receptor-modified t cell and use thereof |
WO2022155421A1 (en) | 2021-01-15 | 2022-07-21 | University Of Rochester | Staphylococcus aureus antigen-based nucleic acid vaccines |
WO2022165111A1 (en) | 2021-01-28 | 2022-08-04 | Precision Biosciences, Inc. | Modulation of tgf beta signaling in genetically-modified eukaryotic cells |
WO2022162192A2 (en) | 2021-01-29 | 2022-08-04 | Thelper As | Therapeutic and diagnostic agents and uses thereof |
WO2022166665A1 (en) | 2021-02-08 | 2022-08-11 | 浙江大学 | Chimeric antigen receptor with endogenous protein molecule replacing single domain antibody |
US11730764B2 (en) | 2021-02-16 | 2023-08-22 | A2 Biotherapeutics, Inc. | Compositions and methods for treating HER2 positive cancers |
WO2022226296A2 (en) | 2021-04-23 | 2022-10-27 | University Of Rochester | Genome editing by directed non-homologous dna insertion using a retroviral integrase-cas fusion protein and methods of treatment |
WO2022254337A1 (en) | 2021-06-01 | 2022-12-08 | Novartis Ag | Cd19 and cd22 chimeric antigen receptors and uses thereof |
WO2022262764A1 (en) | 2021-06-16 | 2022-12-22 | 四川大学华西医院 | Preparation and application of lox1-based chimeric antigen receptor immune cell |
WO2022262765A1 (en) | 2021-06-16 | 2022-12-22 | 四川大学华西医院 | Preparation and application of chimeric antigen receptor immune cell constructed on basis of granzyme b |
US11945876B2 (en) | 2021-06-16 | 2024-04-02 | Instil Bio (Uk) Limited | Receptors providing targeted costimulation for adoptive cell therapy |
WO2022266660A1 (en) | 2021-06-17 | 2022-12-22 | Amberstone Biosciences, Inc. | Anti-cd3 constructs and uses thereof |
WO2022271955A1 (en) | 2021-06-23 | 2022-12-29 | Musc Foundation For Research Development | Novel targeted shrna nanoparticles for cancer therapy |
WO2023278641A1 (en) | 2021-06-29 | 2023-01-05 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
WO2023283611A1 (en) | 2021-07-08 | 2023-01-12 | Staidson Biopharma Inc. | Antibodies specifically recognizing tnfr2 and uses thereof |
WO2023284714A1 (en) | 2021-07-14 | 2023-01-19 | 舒泰神(北京)生物制药股份有限公司 | Antibody that specifically recognizes cd40 and application thereof |
US11697677B2 (en) | 2021-07-16 | 2023-07-11 | Instil Bio (Uk) Limited | Chimeric molecules providing targeted costimulation for adoptive cell therapy |
WO2023056329A1 (en) | 2021-09-30 | 2023-04-06 | Akouos, Inc. | Compositions and methods for treating kcnq4-associated hearing loss |
WO2023069979A1 (en) | 2021-10-20 | 2023-04-27 | University Of Rochester | Isolated glial progenitor cells for use in the competition treatment of age-related white matter loss |
WO2023069987A1 (en) | 2021-10-20 | 2023-04-27 | University Of Rochester | Rejuvenation treatment of age-related white matter loss cross reference to related application |
WO2023081633A1 (en) | 2021-11-02 | 2023-05-11 | University Of Rochester | Tcf7l2 mediated remyelination in the brain |
WO2023086939A1 (en) | 2021-11-12 | 2023-05-19 | Amicus Therapeutics, Inc. | Compositions and methods for treating mucopolysaccharidosis iiia |
WO2023089556A1 (en) | 2021-11-22 | 2023-05-25 | Pfizer Inc. | Reducing risk of antigen mimicry in immunogenic medicaments |
WO2023105005A1 (en) | 2021-12-09 | 2023-06-15 | BioNTech SE | Chimeric antigen receptor-modified cells for the treatment of cldn6 expressing cancer |
WO2023144779A1 (en) | 2022-01-28 | 2023-08-03 | Pfizer Inc. | Coronavirus antigen variants |
WO2023144392A1 (en) | 2022-01-28 | 2023-08-03 | Thelper As | Therapeutic and diagnostic agents and uses thereof |
WO2023177954A1 (en) | 2022-03-18 | 2023-09-21 | University Of Rochester | Combination therapy for treatment of cancer, methods and systems of delivery thereof |
WO2023215860A1 (en) | 2022-05-05 | 2023-11-09 | University Of Rochester | Modified bacteria and methods of use for bioglass microlenses |
WO2024020407A1 (en) | 2022-07-19 | 2024-01-25 | Staidson Biopharma Inc. | Antibodies specifically recognizing b- and t-lymphocyte attenuator (btla) and uses thereof |
WO2024046572A1 (en) | 2022-09-01 | 2024-03-07 | BioNTech SE | Chimeric antigen receptor-modified cells for the treatment of cldn6 expressing cancer |
WO2024056809A1 (en) | 2022-09-15 | 2024-03-21 | Novartis Ag | Treatment of autoimmune disorders using chimeric antigen receptor therapy |
Also Published As
Publication number | Publication date |
---|---|
AU2001275474A1 (en) | 2001-12-24 |
WO2001096584A3 (en) | 2003-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001096584A2 (en) | Materials and methods for the control of nematodes | |
CN107287235B (en) | Down-regulating gene expression in insect pests | |
AU2005299492B2 (en) | Methods and materials for conferring resistance to pests and pathogens of plants | |
RU2671143C2 (en) | Plants resistant to insect pests | |
US5589622A (en) | Plant parasitic nematode control | |
KR102266402B1 (en) | Novel pest control methods | |
CN106413390A (en) | Compositions and methods for controlling insect pests | |
KR20170066404A (en) | Copi coatomer beta subunit nucleic acid molecules that confer resistance to coleopteran and hemipteran pests | |
Youssef et al. | Post-transcriptional gene silencing of the gene encoding aldolase from soybean cyst nematode by transformed soybean roots | |
MX2014000707A (en) | Plants resistant to insect pests. | |
CA2535132A1 (en) | Plants resistant to cytoplasm-feeding parasites | |
TW201321511A (en) | Nucleic acid molecules that target RPS6 and confer resistance to coleopteran pests | |
TW201321509A (en) | Nucleic acid molecules that target PP1-87B and confer resistance to coleopteran pests | |
KR20160093727A (en) | Ras opposite (rop) and related nucleic acid molecules that confer resistance to coleopteran and/or hemipteran pests | |
TW201321508A (en) | Nucleic acid molecules that target RPA70 and confer resistance to coleopteran pests | |
HUE031986T2 (en) | Stress-resistant plants and their production | |
KR20170013885A (en) | Sec23 nucleic acid molecules that confer resistance to coleopteran and hemipteran pests | |
EP0548197B1 (en) | Plant parasitic nematode control | |
JP2018513675A (en) | RNA polymerase II33 nucleic acid molecules for controlling pests | |
WO2007147016A2 (en) | Generation of plants with improved pathogen resistance | |
CN110564740B (en) | A gene AtPIP2 for improving disease resistance of plants; 7 and uses thereof | |
JP2018509150A (en) | RNA polymerase II215 nucleic acid molecules for controlling pests | |
WO2013158966A1 (en) | Bronze bug control agents | |
RU2775717C1 (en) | Polynucleotide and method used to control an insect outbreak | |
KR20170065538A (en) | Gho/sec24b2 and sec24b1 nucleic acid molecules to control coleopteran and hemipteran pests |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |